Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed 289 guidelines under your selection of "Type of cancer". The most recent guidelines are first.

Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline

Year: 2019
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This clinical practice guideline focuses on the early detection of colorectal cancer and the management of polyps found during colorectal cancer screening among those at average risk, as well as the workup and diagnosis of colorectal cancer. The guideline discusses the optimal strategies for population-level early detection of colorectal cancer in high-incidence and resource-constrained settings, the optimal reflex testing strategy for people with positive screening results, the optimal strategy for people with premalignant polyps or other abnormal screening results, and the optimal methods for diagnosing patients who have signs and symptoms of early colorectal cancer. Recommendations are resource-stratified and are tailored to basic, limited, enhanced and maximal resource settings.

Neuroendocrine and Adrenal Tumours, Version 4.2018

Year: 2019
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.

Endoscopic Surveillance After Surgical or Endoscopic Resection for Colorectal Cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline

Year: 2019
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This is a clinical practice guideline for patients who have been operated on for sporadic colorectal cancer (CRC) and for those in whom a low risk T1 CRC has been completely removed at endoscopy. The guideline discusses the endoscopic surveillance of these patients, and provides recommendations on the appropriate timing of endoscopy (i.e. in specific intervals following surgery), and the age at which to halt the use of surveillance endoscopy. Outcomes of interest include overall survival, CRC-specific survival, relapse-free survival, and adverse effects.

Management of Epithelial Precancerous Conditions and Lesions in the Stomach (Maps II): European Society Of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) Guideline Update 2019

Year: 2019
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This is a clinical practice guideline for the management of epithelial precancerous conditions and lesions in the stomach. The guideline specifically addresses the diagnostic assessment, treatment and surveillance of individuals with atrophic gastritis, intestinal metaplasia, and dysplasia of the stomach. Topics discussed include endoscopic diagnosis, biopsies and histology, noninvasive assessment, management, Helicobacter pylori treatment, follow-up, and the cost-effectiveness of surveillance and screening.

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline

Year: 2019
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for patients with resected biliary tract cancer, including cancers of the intrahepatic bile ducts, perihilar and distal extrahepatic bile ducts, and the gallbladder. The guideline provides recommendations on adjuvant therapy, including fluoropyrimidine-based or gemcitabine-based chemotherapy and/or radiation therapy. Outcomes of interest include relapse-free survival (RFS) and overall survival (OS), as well as quality of life (QOL).

Preoperative or Postoperative Therapy for the Management of Patients With Stage II or III Rectal Cancer

Year: 2019
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with clinically resectable or resected stage II or III rectal cancer. The guideline examines the appropriate preoperative staging tests and the role of postoperative radiotherapy (RT) and/or chemotherapy (CT) for patients with resected stage II or III rectal cancer. The primary outcomes of interest are increase in overall survival and delaying local recurrence.

Evidenced-Based Guideline for Colorectal Cancer

Year: 2019
AGREE II score: Available
Developer organization: German Guideline Program in Oncology
This is a clinical practice guideline for physicians who work on the prevention and treatment of colorectal cancer in the ambulatory and inpatient sector. The guideline provides recommendations for prevention, screening in asymptomatic populations as well as high risk populations, the role of endoscopy in the diagnosis of polyps and colorectal cancer, pre-operative diagnostics and surgery, adjuvant and neoadjuvant therapy, management of patients with metastases, palliative care and follow-up care.

Hepatobiliary Cancers, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.

Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion

Year: 2018
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This provisional clinical opinion addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma. Recommendations are provided around the appropriate methods for determining patients' susceptibility to developing pancreatic cancer, which individuals should undergo genetic testing, and the surveillance strategies that should be used for individuals with predispositions to pancreatic ductal adenocarcinoma to screen for pancreatic and other cancers.

Metastatic Colorectal Cancer

Year: 2018
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with metastatic colorectal cancer. The guideline examines treatment options, including different chemotherapy regimens, and metastasectomy. Other topics of discussion include palliative chemotherapy regimens, and treatment of liver metastasis. Outcomes of interest include adverse effects, overall survival, and quality of life.

Pancreatic Adenocarcinoma, Version 1.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.

Endoscopic Eradication Therapy for Patients With Barrett’s Esophagus–Associated Dysplasia and Intramucosal Cancer

Year: 2018
AGREE II score: Available
Developer organization: American Society for Gastrointestinal Endoscopy
This is a clinical practice guideline for patients with Barrett's esophagus (BE), which is the only identifiable premalignant condition for esophageal adenocarcinoma (EAC). The guideline examines endoscopic eradication therapy (EET) and its role in the management of BE-related neoplasia. Outcomes of interest include progression to cancer, cancer-specific and all-cause mortality, adverse events, and recurrence rates.

Colon Cancer, Version 4.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of colon cancer. Recommendations are made for diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, and management of recurrence. Principles for the management of metastatic disease are also provided.

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (Revised 2018)

Year: 2018
AGREE II score: Unavailable
Developer organization: American Society of Colon and Rectal Surgeons
This is a clinical practice guideline for patients with squamous cell cancers (SCC) of the anal canal and perianal region. The guideline specifically examines management options for premalignant and malignant squamous neoplasms of the anus and perianal region. Recommendations are provided regarding screening options, primary treatment, and surveillance for SCC and perianal squamous cell cancers.

Colorectal Cancer Screening, Version 1.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline discussing colorectal cancer (CRC) screening in adults. Recommendations are made for three groups of patients, stratified by their risk of developing CRC: average risk, increased risk, and high risk syndromes. Screening modalities examined include structural screening tests, such as colonoscopy, flexible sigmoidoscopy, and computed tomographic colonography, as well as fecal-based tests, which include fecal occult blood test, and combined stool deoxyribonucleic acid/fecal immunochemical (DNA/FIT) tests.

Colon Cancer, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of colon cancer. Recommendations are made for diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, and management of recurrence. Principles for the management of metastatic disease are also provided.

Anal Carcinoma, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline is for the management of squamous cell anal carcinoma. The guideline provides recommendations on staging, treatment, and follow-up. The effectiveness of treatment options such as surgery, chemotherapy, and radiation therapy are compared. Guidance is also provided on dosing regimens, treatment of recurrence, and surveillance following treatment of recurrence.

ACR Appropriateness Criteria Colorectal Cancer Screening

Year: 2018
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for individuals with average, moderate, or high risk of developing colorectal cancer. The guideline the examines the appropriateness of various screening procedures including computed tomography (CT) colonography, X-ray barium enema double-contrast, magnetic resonance colonography, and X-ray barium enema single-contrast. The guideline also considers age, family medical history of colorectal cancer, and presence of other conditions or risk factors.

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2018
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for adult oncology patients with neutropenia. The guideline examines the appropriate prescribing of filgrastim for these patients. Indications for which filgrastim should be used are discussed by disease site group. Disease site groups considered include breast, central nervous system, gastrointestinal, gynecologic, genitourinary, hematologic, and thoracic, amongst others.

The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with RAS wild-type unresectable metastatic colorectal cancer (mCRC) who are undergoing first-line or second-line chemotherapy. The guideline provides recommendations on the role of primary tumour location (PTL) in the selection of epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and vascular endothelial growth factor (VEGF) inhibitors, in addition to chemotherapy for the treatment of unresectable mCRC.

Oesophago-Gastric Cancer: Assessment and Management in Adults

Year: 2018
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for adults with newly-diagnosed or recurrent oesophago-gastric cancer. The guideline discusses clinical assessment, radical and palliative treatment, follow-up, nutritional support, and service organization. The primary outcomes of interest are increases in quality of life and survival.

Cancer in People Living With HIV, Version 1.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

Hepatobiliary Cancers, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.

Provincial Esophageal Cancer and Gastro-Esophageal Junction Cancer Treatment Guidelines

Year: 2018
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for adult patients with esophageal cancer or cancer of the gastro-esophageal junction. The guideline provides recommendations on assessment, systemic therapy, surgical approaches, and post-curative therapy follow-up of these patients. The discussion of treatment is stratified by stage, performance status, and disease type. Chemotherapy regimens are also considered.

Rectal Cancer, Version 3.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of rectal cancer. The guideline provides recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, and patient surveillance. Outcomes of interest include safety and efficacy of treatment, adverse outcomes, and overall survival.

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update

Year: 2018
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for patients with metastatic pancreatic cancer. The guideline examines the appropriate therapy for patients with metastatic pancreatic cancer who experience either disease progression or intolerable toxicity with prior regimens. Options for routine testing of patients who are considered to be candidates for checkpoint inhibitor therapy are discussed, as are programmed cell death-1 (PD-1) immune checkpoint inhibitor pembrolizumab as second-line therapy, and the use of fluorouracil with either nanoliposomal irinotecan, irinotecan, or oxaliplatin.

Cancer in People Living with HIV, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

Pancreatic Adenocarcinoma, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.

Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus

Year: 2018
AGREE II score: Available
Developer organization: Canadian Association of Gastroenterology
This is a clinical practice guideline for adults with a family history of nonhereditary colorectal cancer (CRC) or adenoma. The guideline discusses screening for CRC in these individuals, and provides specialized recommendations based on the number of affected relatives, whether or not the relatives have CRC or colorectal adenoma, the severity of the relatives' disease, as well as how related the relatives are to the patient (i.e. first degree versus second degree relatives).

Pancreatic Cancer in Adults: Diagnosis and Management

Year: 2018
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for adults with suspected pancreatic cancer, or those with newly diagnosed or recurrent pancreatic ductal adenocarcinoma. The guideline provides recommendations for the monitoring of people with an inherited high risk of pancreatic cancer. Recommendations are also made for diagnosis, staging, psychological support, pain and nutrition management, as well as management for resectable, borderline resectable, and unresectable cancer.

Neuroendocrine and Adrenal Tumors, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.

AASLD Guidelines for the Treatment of Hepatocellular Carcinoma

Year: 2018
AGREE II score: Available
Developer organization: American Association for the Study of Liver Diseases
This is a clinical practice guideline for hepatocellular carcinoma (HCC) occurring in adult patients with cirrhosis. The guideline examines techniques for surveillance and screening, diagnostic evaluation methods, and the various therapeutic options for the treatment of HCC. Outcomes of interest include the sensitivity and specific of screening tests, as well as morbidity, recurrence, and survival.

Gastric Cancer, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults and children with gastric cancer. The guideline examines the pathology, initial workup, staging, treatment, follow-up, and supportive care of these patients. Treatment options discussed include lymph node dissection, laparoscopic resection, endoscopy, radiation therapy, combined modality therapy, chemotherapy (preoperative, perioperative, and postoperative), and targeted therapies.

Esophageal and Esophagogastric Junction Cancers, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults with esophageal or esophagogastric junction cancer. The guideline examines the initial workup, histological staging, primary treatment, and follow-up of both squamous cell carcinoma and adenocarcinoma. Treatment modalities discussed include surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies.

Rectal Cancer, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of rectal cancer. The guideline provides recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, and patient surveillance. Outcomes of interest include safety and efficacy of treatment, adverse outcomes, and overall survival.

Referral of Patients With Suspected Colorectal Cancer by Family Physicians and Other Primary Care Providers

Year: 2017
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
This clinical practice guideline provides recommendations on the referral of patients with signs and/or symptoms of colorectal cancer (CRC) by family physicians and other primary care providers. The guideline reviews signs, symptoms, and other clinical features that may be indicative of CRC and that warrant additional investigation. Referral wait time recommendations are provided, along with recommendations to reduce diagnostic delay. Additionally, known risk factors that increase the likelihood of CRC in patients with signs and/or symptoms of CRC are reviewed.

Hepatocellular Carcinoma

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults with hepatocellular carcinoma (HCC). The guideline examines the goals of therapy, and provides recommendations for the treatment of patients with different stages of HCC, from very early stages to terminal stage. Outcomes of interest include rendering the patient free of disease, preventing recurrence, and improving quality of life.

Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes

Year: 2017
AGREE II score: Unavailable
Developer organization: American Society of Colon and Rectal Surgeons
This is a clinical practice guideline for men and women with inherited polyposis syndromes. The guideline examines the identification and management of familial adenomatosis polyposis (FAP), attenuated FAP, MutY homologue-associated polyposis (MAP), and polyposis without an identified genotype. Extraintestinal manifestations included in the adenomatous polyposis syndromes are also discussed.

Recommendations for Reporting Tumor Budding in Colorectal Cancer Based on the International Tumor Budding Consensus Conference (ITBCC) 2016

Year: 2017
AGREE II score: Unavailable
Developer organization: United States and Canadian Academy of Pathology
This is a clinical practice guideline for patients with colorectal cancer. The guideline examines tumour budding as a prognostic factor in these patients. The definition of tumour budding, clinical scenarios and tumour budding, H&E and immunohistochemistry for the tumour budding score, intratumoural and peritumoural budding, field number and size for the tumour budding score, cut-offs and continuous scale for the tumour budding score, and reporting tumour budding are all discussed.

Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
This is a clinical practice guideline on the use of fecal immunochemical testing (FIT) in colorectal cancer screening. Guidance is provided on the application of FIT and FIT-based screening programs, including recommendations on the number of tests, screening intervals and cut-off values. The guideline also compares the effectiveness of FIT relative to other colorectal screening tests. Outcomes of interest include sensitivity, specificity and adherence rates.

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer

Year: 2017
AGREE II score: Available
Developer organization: The US Multi-Society Task Force on Colorectal Cancer
This is a clinical practice guideline for the screening of colorectal cancer. Recommendations are provided for specific screening tests, and for the various approaches used to determine when and to whom screening should be offered. Screening tests discussed include colonoscopy, fecal immunochemical test, and computed tomography (CT) colonography. Cost issues, quality of screening, practical considerations, and family history are also discussed.

Genetic/Familial High-Risk Assessment: Colorectal

Year: 2017
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the assessment of patients who are at high risk for colorectal cancer due to genetic or familial factors. The guideline provides recommendations for the management of patients with high-risk syndromes, including Lynch syndrome, familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome (PJS), Juvenile Polyposis Syndrome (JPS), Serrated Polyposis Syndrome (SPS), and other high-risk syndromes associated with colorectal cancer risk.

Early Stage Colon Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with early stage colon cancer. The guideline discusses diagnostic work-up, staging, and treatment options. Recommendations for adjuvant chemotherapy are presented, based on cancer stage.

Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: The US Multi-Society Task Force on Colorectal Cancer
This is a consensus statement providing recommendations to assist health care providers with the appropriate management of patients with biallelic mismatch repair deficiency (BMMRD) syndrome, also called constitutional mismatch repair deficiency syndrome. The guideline outlines what is known about BMMRD, the unique genetic and clinical aspects of the disease, and reviews the current management approaches taken.

Adenocarcinoma of the Pancreas

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for the management of adult patients with adenocarcinoma of the pancreas. The guideline provides recommendations on diagnostic work-up, staging, and treatment options based on stage of cancer. Specific topics discussed include management recommendations for unresectable adenocarcinoma, and toxicity-associated dose modification. Outcomes of interest include adverse events, overall survival, and quality of life.

Staging and Surgical Approaches in Gastric Cancer

Year: 2017
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adults with Stage I to IV gastric cancer (specifically gastric adenocarcinoma) who are being considered for surgery. The guideline examines the optimal techniques to adequately stage gastric cancer, and the optimal techniques of gastric cancer surgery with curative intent. The guideline also considers indications for surgery for Stage IV gastric cancer in asymptomatic and symptomatic patients, and the relationship between surgical volumes and outcomes.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Year: 2017
AGREE II score: Available
Developer organization: Clinical Pharmacogenetics Implementation Consortium
This is a clinical practice guideline for patients with colorectal cancer, breast cancer, or cancers of the aerodigestive tract, who are being considered for treatment with fluoropyrimidines (5-fluorouracil and capecitabine). The guideline provides recommendations for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide fluoropyrimidine dosage. The primary outcome of interest is reduced toxicity among individuals with subnormal DPYD metabolism.

ACR Appropriateness Criteria Suspected Liver Metastases

Year: 2017
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for the assessment of liver metastases. The guideline provides recommendations regarding the appropriateness of imaging modalities and the optimization of imaging parameters for specific clinical scenarios, including diagnosis, staging, and surveillance. Outcomes of interest include accuracy in characterizing and detecting liver lesions, length of examination, and potential adverse health effects, as well as surveillance sensitivity, specificity, and reproducibility.

ACR Appropriateness Criteria Staging of Pancreatic Ductal Adenocarcinoma

Year: 2017
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for adults and children with pancreatic ductal adenocarcinoma. Different variations of imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US) are discussed. The guideline examines the appropriateness of these techniques for two clinical situations: during initial staging before treatment, and following neoadjuvant therapy to evaluate tumour resectability for borderline resectable tumours.

Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Year: 2017
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This clinical practice guideline is a focused update of the American Society of Clinical Oncology's 2016 guideline titled Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. The update focuses solely on new evidence that pertains to clinical question 4 of the guideline: What is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primary tumour? Outcomes of interest include treatment efficacy, and improved survival.

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Colon Cancer

Year: 2017
AGREE II score: Available
Developer organization: American Society of Colon and Rectal Surgeons
This is a clinical practice guideline for patients diagnosed with colon cancer. The guideline examines the evaluation, staging, and treatment of these patients. Surgical treatment of the primary tumour is discussed, as well as treatment of tumour-related emergencies, management of stage 4 disease, management of locoregional recurrence, documentation, and adjuvant therapy.

Clinical Practice Guidelines for the Surgical Treatment of Patients With Lynch Syndrome

Year: 2017
AGREE II score: Unavailable
Developer organization: American Society of Colon and Rectal Surgeons
This is a clinical practice guideline for patients with Lynch syndrome (LS). The guideline examines screening, prevention, and treatment of cancer in these patients. Specifically, screening tests for endometrial, ovarian, gastric, small intestinal, pancreatic, breast, and prostate cancers, as well as cancers of the urinary tract, are discussed. Prophylactic hysterectomy and oophorectomy, tumour testing, germline testing, and LS management are also examined.

Management of Pancreatic Cancer Part 3: Neoadjuvant and Induction Therapy

Year: 2017
AGREE II score: Available
Developer organization: Belgian Healthcare Knowledge Centre
This clinical practice guideline is part three of a series focusing on the management of pancreatic cancer (PC). The guideline focuses on the neoadjuvant and induction therapies for PC and locally advanced pancreatic cancer (LAPC). Comparisons are made between the clinical effectiveness of neoadjuvant treatment with chemotherapy, radiotherapy or both.

Colorectal Polypectomy and Endoscopic Mucosal Resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE)

Year: 2017
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This is a clinical practice guideline for patients with colorectal polyps. The guideline examines the use of polypectomy and endoscopic mucosal resection (EMR) in colonoscopy and for colorectal cancer (CRC) prevention. Polyp classification, polypectomy for polyps smaller than 20mm, EMR for polyps 20mm or larger, technical considerations, adverse events, and histopathology are discussed.

Management of Pancreatic Cancer Part 2: Diagnosis

Year: 2017
AGREE II score: Available
Developer organization: Belgian Healthcare Knowledge Centre
This clinical practice guideline is part two of a series focusing on the management of pancreatic cancer (PC). The guideline focuses on the diagnosis of pancreatic cancer, and provides recommendations regarding imaging tests such as endoscopic ultrasound (EUS), positron emission tomography (PET), and laparoscopy. The use of serum biomarkers during diagnostic work-up, and tests to assess curative resectability of pancreatic tumours, are also discussed.

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates

Year: 2017
AGREE II score: Unavailable
Developer organization: International Liver Transplantation Society
This is a clinical practice guideline for patients with hepatitis C virus (HCV) infection who are candidates for liver transplantation (LT). Specifically, the guideline provides recommendations on the treatment of patients with compensated cirrhosis and hepatocellular carcinoma (HCC), the treatment of patients with decompensated cirrhosis with or without HCC, the management of HCV in the context of an anti-HCV-positive donor, the treatment of post-transplant severe cholestatic hepatitis, the treatment of recurrent HCV infection, the treatment of recurrent HCV cirrhosis, and the treatment of HCV pre- and post-LT in human immunodeficiency virus (HIV)-HCV co-infected patients. Outcomes of interest differ between specific patient populations, and include wait-list mortality, post-LT survival, HCV recurrence post-LT, and the development of extrahepatic complications.

Management and Follow-Up of Gallbladder Polyps

Year: 2017
AGREE II score: Available
Developer organization: European Society of Gastrointestinal and Abdominal Radiology
This is a clinical practice guideline for patients with incidentally detected gallbladder polyps. The guideline examines the management and follow-up of these patients. Specific topics addressed include which patients require cholecystectomy, which patients require ultrasound follow-up, and what the frequency and duration of follow-up should be.

Quality Standards in Upper Gastrointestinal Endoscopy: A Position Statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS)

Year: 2017
AGREE II score: Available
Developer organization: British Society of Gastroenterology
This is a clinical practice guideline on the use of endoscopy for the diagnosis of upper gastrointestinal (UGI) cancers. Pre-procedural, procedural, post-procedural, and disease-specific recommendations are provided. The primary outcome of interest is to optimize the diagnosis of early neoplasia and premalignant conditions of the upper gastrointestinal tract, in order to reduce the effects of UGI cancers which are often associated with a poor prognosis due to late detection.

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology

Year: 2017
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This clinical practice guideline focuses on molecular biomarker testing for patients with early and advanced colorectal cancer. The recommendations are intended to help establish standard molecular biomarker testing, guide decisions on whether or not to use epidermal growth factor receptor (EGFR)-targeted therapy, and to ensure that the most effective and advance personalized care is delivered to patients.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology

Year: 2016
AGREE II score: Available
Developer organization: College of American Pathologists
This is a clinical practice guideline for patients with gastroesophageal adenocarcinoma. The guideline provides recommendations for the assessment of HER2 (or erb-b2 receptor tyrosine kinase (ERBB2)) mutations, while addressing which patients and tumour specimens are appropriate. Outcomes of interest include increased accuracy of HER2 testing, and increased utility for clinician decision-making.

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline to guide appropriate prescribing of filgrastim in adults. The guidelines looks at a variety of disease sites and is intended as a guide to facilitate a shared approach to the appropriate use of filgrastim. In order provide clarity surrounding the indications in which filgrastim should be used, the recommendations are presented by disease site.

Tobacco Screening and Treatment for Adult Cancer Patients

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults (aged 18 and older) at any phase of the cancer care continuum regardless of cancer type, stage (including metastatic) or treatment plan, with some components of the guideline also applicable to the patient's family and/or caregivers. Recommendations are provided on implementation of the brief tobacco intervention using the evidence-based AAR Brief Tobacco Intervention Model which includes screening, education and assessment, treatment plan, and referral, monitoring, and follow-up. The 2015 guideline was revised in June 2016 to abbreviate the cessation intervention model to best support adoption across all CCA clinics and settings. Clinical considerations and contraindications of treatment options for cancer patients are discussed including nicotine replace therapy (NRT), bupropion, varenicline, and e-cigarettes, and the impact of tobacco use on cancer treatment is reviewed with a specific focus on erlotinib and irinotecan.

Gastrointestinal Stromal Tumours (GIST)

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients with gastrointestinal stromal tumours. The guideline examines appropriate imaging modalities, and treatment for newly diagnosed and metastatic tumours. Outcomes of interest include disease progression and recommended imaging.

Myeloid Growth Factors – Version 2.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the use of myeloid growth factors in adult patients with solid tumours and non-myeloid malignancies. Benefits and risks are reviewed, the role of biosimilars is discussed, and recommendations are provided for prophylactic and therapeutic uses of both granulocyte and granulocyte-macrophage colony stimulating factors (CSFs). Recommendations are also given regarding the use of CSFs in the hematopoietic cell transplant setting. Outcomes of interest include efficacy of CSFs, mortality, length of hospitalization, toxicity, and adverse effects.

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement

Year: 2016
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is an update to the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for colorectal cancer. The USPSTF reviewed the evidence on the effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 DNA test in reducing the incidence of and mortality from colorectal cancer or all-cause mortality. Other topics discussed in the guideline include: the harms of these screening tests; and the test performance characteristics of these tests for detecting adenomatous polyps; as well as information on optimal starting and stopping ages and screening intervals across the different available screening methods.

ACR Appropriateness Criteria Borderline and Unresectable Pancreas Cancer

Year: 2016
AGREE II score: Available
Developer organization: American College of Radiology
This clinical practice guideline provides recommendations on the diagnosis and treatment of locally advanced and borderline resectable pancreatic cancer. Radiotherapy alone is compared to chemoradiation for treatment of locally advanced disease, and preoperative therapy for borderline resectable disease is discussed. The guideline reviews neoadjuvant systemic therapy followed by local treatment and provides recommendations on chemotherapy regimes. Outcomes of interest include progression-free survival, median survival, 1-year survival, and local control.

Cancer of the Upper Aerodigestive Tract: Assessment and Management in People Aged 16 and Over

Year: 2016
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This clinical practice guideline provides recommendations on the investigation, treatment, and follow-up care of patients aged 16 years and older with cancer of the upper aerodigestive tract. HPV-related disease and less common upper aerodigestive tract cancers including carcinoma of the nasopharynx or paranasal sinuses, unknown primary of presumed upper aerodigestive tract origin, and mucosal melanoma, are also reviewed. Additionally, recommendations are provided on optimizing rehabilitation and function. Outcomes of interest include prevalence, predictive value, sensitivity, specificity, local control, survival (overall, progression-free), treatment-related morbidity and mortality, and resource use, among others.

SEOM Clinical Guideline for Gastrointestinal Sarcomas (GIST) (2016)

Year: 2016
AGREE II score: Unavailable
Developer organization: Spanish Society of Medical Oncology
This is a clinical practice guideline for the diagnosis, treatment and follow-up of patients with gastrointestinal stromal tumours (GISTs). The guideline discusses the diagnosis of GISTs using radiology, histology and molecular biology, while also providing recommendations for the treatment of both localized and advanced disease. Surgery, adjuvant and neoadjuvant treatment options are specifically examined.

Systemic Therapy of Incurable Gastroenteropancreatic Neuroendocrine Tumours

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adults diagnosed with incurable gastroenteropancreatic neuroendocrine tumours. The guideline examines treatment options for pancreatic neuroendocrine tumours and non-pancreatic neuroendocrine tumours, including chemotherapy, targeted therapy, somatostatin analogues and interferon, and combination therapy. Outcomes of interest include progression-free and overall survival, adverse events, and quality of life.

Metastatic Colorectal Cancer

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for the treatment of adult patients with metastatic colorectal cancer. The guideline examines different management options, including treatment via clinical trials, treatment chemotherapy, palliative chemotherapy, EGFR inhibitors, and regorafenib (as a fourth-line therapy). The guideline also discusses the need to test for Ras mutations before treatment. Outcomes of interest include treatment efficacy and improved survival outcomes.

Malignant Biliary Obstruction

Year: 2016
AGREE II score: Available
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with neoplasms causing biliary obstruction. The guideline examines the management of malignant biliary obstructions, including diagnostic work-up and treatment options. Recommendations are provided based on factors such as the resectability and location of the obstruction. Outcomes of interest include improved quality of life (QOL) and prolonged survival.

Guidelines for the Investigation of Patients With Symptoms Suggestive of Colorectal Cancer

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Nova Scotia
This is a clinical practice guideline for adult patients in primary care settings or emergency departments who have signs and symptoms suggestive of colorectal cancer (CRC). The guideline examines how to define expectations for primary care providers (PCPs), endoscopists, and radiologists regarding the appropriate work up of patients who have symptoms suggestive of colorectal cancer, and outlines the communication expectations between PCPs, endoscopists, radiologists, and other health care providers and patients. Outcomes of interest include effective communication, as well as early and accurate diagnoses.

Gastric Cancer – Version 3.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for gastric cancer. The guideline provides an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. Topic areas discussed within the guideline include: staging, principles of pathology, surgery, endoscopic therapies, radiation therapy, combined modality therapy, chemotherapy, and follow-up.

Rectal Cancer – Version 2.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with colon cancer. The guideline reviews risk assessment, TNM staging, and pathology, and provides recommendations on the clinical presentation and treatment of nonmetastatic disease as well as recommendations on management of metastatic disease. Treatment for locally recurrent disease and survivorship are also discussed, as is the role of vitamin D in colorectal cancer.

ACR Appropriateness Criteria Resectable Pancreatic Cancer

Year: 2016
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for patients with resectable pancreatic cancer. The guideline reviews biomarkers, specifically carbohydrate antigen 19-9 (CA19-9), and SMAD4 (DPC4), as well as other prognostic factors such as resection margin status and lymph node involvement. Adjuvant therapy, neoadjuvant therapy, and radiotherapy are discussed as treatment options, taking patient risk factors for local recurrence into consideration.

The Role of Endoscopy in the Evaluation and Management of Patients With Solid Pancreatic Neoplasia

Year: 2016
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
This clinical practice guideline discusses the evaluation and treatment of patients with suspected solid pancreatic neoplasia. The guideline reviews presentation and clinical evaluation of pancreatic neoplasia, and provides an overview of radiologic and endoscopic modalities for adenocarcinoma of the pancreas, neuroendocrine tumours (NETS) of the pancreas, solid pseudopapillary tumours (SPTs), metastatic disease, and lymphoma. Screening for pancreatic cancer is also discussed. Outcomes of interest include sensitivity and specificity, as well as adverse events.

Guideline on the Management of Rectal Cancer

Year: 2016
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for patients with rectal cancer. The guideline provides recommendations on use of MRI for staging, optimal surgical techniques for patients with T1-T2 anal cancer with comparisons made between local resection or transanal endoscopic microsurgical resection and radical resection, and the use of adjuvant chemotherapy for patients who have received neoadjuvant radiotherapy (RT). Outcomes of interest include survival (overall, disease free, metastasis-free, local recurrence free), and quality of life.

Palliative Radiotherapy: Bleeding and Gastrointestinal Obstruction

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for palliative oncology patients 18 years of age or older with low grade/ low volume/ malignancy-associated urogenital or gastrointestinal bleeding, or with malignant gastrointestinal obstruction, compression or invasion. External beam radiotherapy (EBRT) with or without , brachytherapy, stent placement, and surgical bypass are discussed as therapeutic options. Outcomes of interest include clinical improvement of symptoms, quality of life, and survival.

Neuroendocrine Tumors – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the screening, diagnosis, staging, and treatment of neuroendocrine tumors. This guideline provides recommendations on issues including: multiple endocrine neoplasia, surveillance of resected neuroendocrine tumors of the gastrointestinal tract, lung, and thymus, and genetic counseling/testing in pheochromocytomas/paragangliomas. Most of the guideline sections pertain to well-differentiated, low- to intermediate-grade tumors, although poorly differentiated/high-grade/large or small cell carcinomas are also addressed.

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2016
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for the treatment of patients with metastatic pancreatic cancer. This clinical practice guideline addresses six overarching clinical questions: After a histopathologic confirmation of pancreatic adenocarcinoma diagnosis, what initial assessment is recommended before initiating any therapy for metastatic pancreatic cancer? What is the appropriate first-line treatment of patients with metastatic pancreatic cancer? What is the appropriate therapy for patients with metastatic pancreatic cancer who experience either disease progression or intolerable toxicity with prior regimens for metastatic pancreatic cancer? When should the concept of palliative care be introduced? For patients with metastatic pancreatic cancer, what are the recommended strategies for relief of pain and symptoms? What is the recommended frequency of follow-up care/surveillance for patients with metastatic pancreatic cancer?

Clinical Standards for the Treatment of Rectal Cancer in Nova Scotia

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Nova Scotia
This guideline discusses the clinical standards of care for the treatment of rectal cancer in Nova Scotia with all aspects of rectal cancer care covered, from diagnosis to survivorship and/or palliation. This includes recommended standards for professionals involved in care, pretreatment investigations, and surgical, neo-adjuvant, and adjuvant treatments. Other topics covered include lynch syndrome screening and referral to medical genetics. Psychosocial health services and supportive care recommendations are also reviewed.

Colon Cancer – Version 2.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with colon cancer or adenocarcinomas of the small bowel and appendix. The guideline reviews staging, pathology, clinical presentation and treatment of nonmetastatic disease, management of metastatic disease, post-treatment surveillance, and survivorship. The role of vitamin D in colorectal cancer is also discussed.

Optimization of Surgical and Pathological Quality Performance in Radical Surgery for Colon and Rectal Cancer: Margins and Lymph Nodes

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for the staging and treatment of colorectal cancer. The guideline focuses on surgical and pathological considerations for the resection of colorectal cancer and provides recommendations on the technique and extent of resection, as well as the reporting of resection results. Outcomes of interest include overall survival, disease-free survival, recurrence rates, and margin status.

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement

Year: 2016
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is a clinical practice guideline for the screening of colorectal cancer in asymptomatic adults. The guideline discusses colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 DNA test as methods of screening. Outcomes of interest include reductions in all-cause mortality, mortality from colorectal cancer, and incidence of colorectal cancer. Screening intervals, age of initiation, and age of termination are determined for different screening methods, via a modeling approach.

Esophageal Stenting for Benign and Malignant Disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline

Year: 2016
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This guideline aims to described the role of esophageal stents in patients with malignant or benign esophageal disease and makes recommendations on circumstances that warrant their use. Questions addressed in this guideline include: what are the results for palliative stent placement compared to other treatment modalities; what are the short-term and long-term adverse events of stent placement; and can stents be used to treat benign esophageal leaks and perforations.

Anal Carcinoma – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with anal carcinoma. Risk factors are discussed and recommendations are provided on risk reduction including HIV immunization, work up, management, and follow-up care. Treatment options are reviewed, with specific recommendations provided for primary treatment of: non-metastatic anal carcinoma, anal canal cancer, and anal margin cancer, as well as treatment for metastatic cancer and for locally progressive or recurrent anal carcinoma. Special considerations are made regarding treatment of anal cancer in patients with HIV/AIDS.

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2016
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This clinical practice guideline provides evidence-based recommendations to oncologists and others for treatment of patients with locally advanced, unresectable pancreatic cancer (LAPC). The guideline addresses a number of key clinical questions including: what initial assessment is recommended before initiating therapy for LAPC; what is the appropriate initial treatment approach for people diagnosed with LAPC; and for people with LAPC, what are the recommended strategies for relief of pain and symptom burden.

Colorectal Cancer Screening Version – 1.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients at average or increased risk of developing sporadic colorectal cancer (patients with high risk colorectal cancer syndromes are not discussed). The guideline discusses risk assessment and provides recommendations for screening modality and schedule stratified by risk. Patients with increased risk include those with a personal history of adenomatous or sessile serrated polyps, colorectal cancer, inflammatory bowel disease, and/or positive family history of colorectal cancer. Screening tests include colonoscopy, flexible sigmoidoscopy computed tomographic colonography, and fecal-based screening.

Fertility Drugs and Cancer: A Guideline

Year: 2016
AGREE II score: Unavailable
Developer organization: American Society for Reproductive Medicine
This clinical practice guideline examines the impact of fertility drugs on the risk of cancer in women. The guideline looks at the association between use of fertility drugs and increased risk of developing invasive ovarian, breast, endometrial, colon and thyroid cancers as well as non-Hodgkin lymphoma and malignant melanoma. The association between fertility drugs and borderline ovarian tumours is also examined.

Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer

Year: 2016
AGREE II score: Available
Developer organization: US Multi-Society Task Force on Colorectal Cancer
This guideline provides recommendations on fecal immunochemical testing (FIT) in screening for colorectal neoplasia. The guideline summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other common screening modalities. Guidance statements on FIT application are developed and quality metrics for program implementation are proposed.

ACR Appropriateness Criteria Pretreatment Staging of Colorectal Cancer

Year: 2016
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for the pretreatment staging of colorectal cancer. Recommendations are made with consideration of two different variants of colorectal cancer: 1. rectal cancer, locoregional staging, and 2. colorectal cancer, staging for distant metastases. The guideline provides recommendations as to the appropriate imaging modalities to be used in the initial staging of colorectal cancer.

Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement

Year: 2016
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is an update to the 2009 recommendation on aspirin use to prevent cardiovascular disease (CVD) events and the 2007 recommendation on aspirin and nonsteroidal anti-inflammatory drug use to prevent colorectal cancer (CRC). The recommendations apply to adults aged 40 years or older without known CVD and without increased bleeding risk. Recommendations include consideration of the aspirin dosage as well as the benefits and harms of initiating aspirin use.

Recommendations on Screening for Colorectal Cancer in Primary Care

Year: 2016
AGREE II score: Available
Developer organization: Canadian Task Force on Preventive Health Care
This is a clinical practice guideline for asymptomatic adults aged 50 years and older who are not at high risk for colorectal cancer. The guideline provides screening recommendations stratified by age group (aged 50-74, and 74 and older). Various screening procedures are discussed and compared including fecal occult blood testing (gFOBT), fecal immunochemical testing, flexible sigmoidoscopy, and colonoscopy. Outcomes of interest include mortality and morbidity, adverse outcomes of screening procedures, test sensitivity and specificity, and positive and negative predictive values.

Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer

Year: 2016
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
This is a clinical practice guideline for the surveillance of patients after colorectal cancer (CRC) resection with curative intent. This guideline focuses on the role of colonoscopy in patients after CRC resection. It also considers the possible adjunctive roles of fecal testing and CTC. Overall, the goal of the guideline is to provide recommendations regarding the role of colonoscopy, flexible sigmoidoscopy, EUS, fecal testing, and CTC in surveillance after surgical resection of CRC.

Thyroid Carcinoma – Version 1.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the diagnosis, staging, and treatment of thyroid carcinoma. Recommendations are stratified by histologic type, namely papillary, follicular, Hürthle cell, medullary, and anaplastic. Primary treatment options and assessment and management after initial treatment is reviewed. Recurrent or persistent disease is also discussed.

Pancreatic Adenocarcinoma – Version 2.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnosis and management of adenocarcinomas of the exocrine pancreas. Risk factors and genetic predisposition are discussed, and the guideline provides recommendations on screening, diagnosis and staging, and treatment options including systemic therapy, chemoradiation, and surgical management. Palliative and supportive care are also reviewed. Topics of interest include an overview of biomarkers, and suggestions for management of premalignant tumours of the pancreas.

Esophageal and Esophagogastric Junction Cancers – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations on esophageal and esophagogastric junction (EGJ) cancers, including: a review of hereditary cancer predisposition syndromes associated with increased risk for esophageal and EGJ cancers, staging and pathology, imaging, and treatment including surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies. Surveillance, management of metastatic, or recurrent cancer, and best supportive care are also discussed. Special topics of interest include treatment and surveillance options for patients with Barrett's esophagus, and suggested strategies to help alleviate the current problems associated with leucovorin shortage.

Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2016
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline provides evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Key recommendations are guided by questions including: what initial assessment is recommended before initiating any therapy for potentially curable pancreatic cancer; what is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone a resection of their primary tumor; and when should palliative care services be initiated for people with pancreatic cancer that is potentially curable by surgery.

Genetic/Familial High-Risk Assessment: Colorectal – Version 2.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations on colorectal screening for patients with high-risk syndromes of inherited colon cancer. Recommendations are provided for management of Lynch syndrome, FAP, MAP, Peutz-Jeghers syndrome, juvenile polyposis syndrome (JPS), SPS, and other high-risk syndromes associated with CRC risk (Li-Fraumeni syndrome [LFS] and Cowden syndrome/PTEN hamartoma tumor syndrome [PHTS]). Topics of discussion include risk assessment and genetic counselling, diagnosis, and preventative treatment options.

Esophageal Cancer

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over 18 years of age with esophageal cancer, including both squamous cell and adenocarcinoma. The guideline provides recommendations on diagnostic work-up, staging, treatment options for potentially curable cancer stratified by stage, and management options for incurable cancer. Esophagectomy, endoscopic therapy, primary chemoradiotherapy, radiotherapy, pre-operative chemoradiotherapy followed by esophagectomy and pre-operative chemotherapy are discussed, as well as supportive care. Outcomes of interest include survival (overall, progression-free, 5-year), morbidity, toxicity, and rate of sudden death.

Preoperative or Postoperative Therapy for Resectable Esophageal Cancer

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with clinically resectable or resected stage II or III rectal cancer. The guideline reviews the use of pre- and post-operative therapy including chemotherapy and radiotherapy as treatment options. Outcomes of interest include survival (overall, cause-specific), quality of life, acute and late toxicities, and postoperative morbidity (within 30 days of surgery).

Follow-up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This clinical practice guideline provides recommendations for follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer. The guideline addresses the following questions which include: what evaluations (e.g., colonoscopy, computed tomography [CT], carcinoembryonic antigen [CEA], liver function, complete blood count [CBC], chest x-ray, history, physical exam) should be performed for surveillance for recurrence of cancer? What is a reasonable frequency of these evaluations for surveillance? Which symptoms and/or signs potentially signify a recurrence of CRC and warrant investigation?

American Association Of Clinical Endocrinologists, American College Of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management Of Thyroid Nodules – 2016 Update

Year: 2016
AGREE II score: Unavailable
Developer organization: American Association of Clinical Endocrinologists
This guideline addresses diagnostic and therapeutic aspects of thyroid nodular disease; thyroid cancer management is not addressed. The guideline provides recommendations on clinical evaluation and diagnosis, thyroid ultrasonography and other imaging studies, thyroid biopsy, laboratory evaluation, radionuclide scanning, and management and therapy of nodules. Special topics of consideration are thyroid nodules during pregnancy and management of thyroid nodules in children.

Focal Tumour Ablation in Ontario: Recommendations Report 2015

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients with a variety of cancers, including lung, liver, and kidney tumours, with a specific focus on patients with hepatocellular carcinoma (HCC) or liver metastases. The guideline examines the effectiveness of thermal ablation, which encompasses radiofrequency ablation (RFA) and microwave ablation, as well as transcatheter arterial chemoembolization (TACE), alone or in combination with other strategies. The guideline outlines patient clinical criteria, criteria for service providers, and system-level criteria.

The Role of Endoscopy in the Diagnosis and Treatment of Cystic Pancreatic Neoplasms

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
This is a clinical practice guideline for the use of GI endoscopy in the evaluation and treatment of pancreatic neoplasms. Diagnosis by endoscopic ultrasound (EUS) is discussed, as is use of EUS-guided-fine needle aspiration (FNA) to determine cytology, chemistries and tumour markers such as CEA, as well as cyst fluid DNA and molecular analysis. Other topics of discussion include emerging techniques for cyst evaluation, adverse events fro EUS, diagnosis by ERCP (Endoscopic Retrograde Cholangio-Pancreatography), and endoscopic treatment of cystic lesions.

Renal Cancer in Adults: Diagnosis, Treatment and Follow-up

Year: 2015
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for adult patients with renal cancer. The guideline examines treatment through surgery and ablative therapy, diagnosis, and follow-up. Outcomes of interest include improved prediction of cancer-specific survival through Karakiewicz nomograms and improved evidence for microwave ablation.

Pancreatic Adenocarcinoma, Version 2.2015

Year: 2015
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnosis and management of adenocarcinomas of the exocrine pancreas. Risk factors and genetic predisposition are discussed, and the guideline provides recommendations on screening, diagnosis and staging, and treatment options including systemic therapy, chemoradiation, and surgical management. Palliative and supportive care are also reviewed. Topics of interest include an overview of biomarkers, and suggestions for management of premalignant tumours of the pancreas.

Colon Cancer, Version 1.2016

Year: 2015
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with colon cancer or adenocarcinomas of the small bowel and appendix. The guideline reviews staging, pathology, clinical presentation and treatment of nonmetastatic disease, management of metastatic disease, post-treatment surveillance, and survivorship. The role of vitamin D in colorectal cancer is also discussed.

EASL-ALEH Clinical Practice Guidelines: Non-Invasive Tests for Evaluation of Liver Disease Severity and Prognosis

Year: 2015
AGREE II score: Unavailable
Developer organization: European Association for the Study of the Liver
This is a clinical practice guideline for the evaluation of liver disease severity and prognosis. The guideline considers the value of liver biopsy for fibrosis evaluation and compares it to other non-invasive tests. The guideline developers considered a number of different questions including: what are the currently available non-invasive tests; how do serum biomarkers perform for staging liver fibrosis; and what are the indications for non-invasive tests for staging liver disease in viral hepatitis.

American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome

Year: 2015
AGREE II score: Available
Developer organization: American Gastroenterological Association
This clinical practice guideline provides recommendations on the diagnosis of Lynch syndrome in patients without a personal history of colorectal or another cancer but with a family history suggestive of Lynch syndrome, as well as for patients with colorectal cancer with IHC absent for MLH1. Management of the risk of colorectal cancer for patients with Lynch syndrome is also discussed with a review of surveillance colonoscopy and recommendations on the use of aspirin as a preventative measure for cancer. Outcomes of interest include sensitivity, specificity, false-positive and false-negative rates of diagnostic tests, as well as psychological distress/quality of life, colorectal cancer incidence, staging, and mortality, Lynch-syndrome associated cancer incidence and mortality, surgical complications from colonoscopy, and costs.

Guidelines for Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection for Early Gastric Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Japan Gastroenterological Endoscopy Society
This is a clinical practice guideline for endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) for early gastric cancer. The guideline provides recommendations for preoperative diagnosis, evaluation of curability, management of complications, long-term postoperative surveillance, and histological assessment. The management of perforation is also specifically discussed.

Guideline for the Management of Bile Duct Cancer by the Brazilian Gastrointestinal Tumor Group

Year: 2015
AGREE II score: Unavailable
Developer organization: Brazilian Gastrointestinal Tumor Group
This is a clinical practice guideline for patients with biliary tract cancers, including gallbladder cancer, intrahepatic and extrahepatic cholangiocarcinoma, and cancer of the duodenal papilla. The guideline examines the diagnosis, staging, and treatment of these patients. Tests discussed for the diagnosis and staging include endoscopic retrograde cholangiopancreatography (ERCP), upper GI endoscopy (UGIE), endoscopic ultrasound (EUS), cholangioscopy, and laparoscopy. Surgical options are stratified by disease type, and both adjuvant treatment and systemic treatment for metastatic cancer of the biliary tract are also discussed.

Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer Following Complete Resection

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Ontario
This clinical practice guideline is for the treatment of patients with stage II and III colon cancer who have undergone complete resection with curative intent. The guideline examines the impact of different adjuvant chemotherapy regimens. Outcomes of interest include overall survival, disease-free survival, adverse events, and quality of life.

Provincial Consensus on Diagnostic and Treatment Recommendations for the Management of Rectal Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This clinical practice guideline provides recommendations on the diagnosis and treatment of rectal cancer in adult patients. Imaging procedures for staging are discussed with comparisons made between ultrasound, MRI, and CT scan. Treatment options include neoadjuvant and adjuvant chemotherapy as well as rectal cancer surgery, specifically total mesorectal excision (TME). Surgical management of recurrent rectal adenocarcinoma is also discussed.

Second-Line Treatment of Advanced Pancreatic Cancer with Oxaliplatin, Fluorouracil and Leucovorin (OFF Regimen)

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with advanced or metastatic pancreatic cancer. The guideline examines the use of oxaliplatin, fluorouracil and leucovorin in patients who had received, or were intolerant to, gemcitabine-based therapy. Outcomes of interest include progression-free and overall survival.

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma

Year: 2015
AGREE II score: Available
Developer organization: Korean Liver Cancer Study Group (KLCSG)
This clinical practice guideline provides recommendations on prevention, diagnosis, and treatment of hepatocellular carcinoma. Treatment options are discussed including surgical resection, transplantation, local ablation, transarterial chemoembolization, external-beam radiation therapy, systemic therapies, preemptive antiviral therapy, and drug treatment for cancer pain. Assessment of tumour response and post-treatment follow-up are also reviewed.

American Cancer Society Colorectal Cancer Survivorship Care Guidelines

Year: 2015
AGREE II score: Available
Developer organization: American Cancer Society
This is a clinical practice guideline for colorectal cancer (CRC) survivors. The guideline reviews methods to identify and manage any physical and psychosocial long-term and late effects of CRC and its treatment, recommendations on surveillance for recurrence and screening for second primary cancers, and health promotion recommendations with detailed discussion about obesity, physical activity, nutrition, and smoking cessation. The guideline also discusses coordination of care among specialists and primary care providers.

Metastatic Colorectal Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for adult patients with metastatic colorectal cancer. The guideline examines treatment, primarily though palliative chemotherapy regimens. Outcomes of interest include delayed disease progression through monoclonal antibodies and improved treatment planning through the identification of RAS testing.

Rectal Cancer, Version 1.2016

Year: 2015
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with colon cancer. The guideline reviews risk assessment, TNM staging, and pathology, and provides recommendations on the clinical presentation and treatment of nonmetastatic disease as well as recommendations on management of metastatic disease. Treatment for locally recurrent disease and survivorship are also discussed, as is the role of vitamin D in colorectal cancer.

Early Rectal Cancer: The European Association for Endoscopic Surgery (EAES) Clinical Consensus Conference

Year: 2015
AGREE II score: Available
Developer organization: European Association for Endoscopic Surgery
This is a clinical practice guideline for patients with early rectal cancer. The guideline provides recommendations on diagnosis, staging, and treatment. Local excision, rectal resection, and total mesorectal excision are discussed as surgical options, and laparoscopic and open approaches to abdominal surgery are compared. The use of neoadjuvant (chemo) radiation therapy is also discussed. Outcomes of interest include diagnostic accuracy, sensitivity, and specificity of diagnostic and staging procedures, local recurrence, survival (5-year, overall, disease free), distant metastases rate, morbidity, and quality of life.

ACR Appropriateness Criteria Resectable Stomach Cancer

Year: 2015
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for patients with resectable gastric cancer. The guideline discusses treatment options such as chemotherapy, radiation therapy, and combined modality treatments such as definitive chemoradiotherapy, preoperative chemoradiotherapy, and postoperative chemoradiotherapy. The guideline also provides an overview of radiation therapy techniques.

Imatinib Mesylate (Gleevec™) for the Treatment of Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Ontario
This clinical practice guideline reviews the use of imatinib in the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing KIT (CD117+). Recommendations are provided on dosage and schedule. Outcomes of interest include overall and progression free survival, and quality of life.

Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2015

Year: 2015
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations on colorectal screening for patients with high-risk syndromes of inherited colon cancer. Recommendations are provided for management of Lynch syndrome, FAP, MAP, Peutz-Jeghers syndrome, juvenile polyposis syndrome (JPS), SPS, and other high-risk syndromes associated with CRC risk (Li-Fraumeni syndrome [LFS] and Cowden syndrome/PTEN hamartoma tumour syndrome [PHTS]). Topics of discussion include risk assessment and genetic counselling, diagnosis, and preventative treatment options.

Gastric Cancer, Version 3.2015

Year: 2015
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for gastric cancer. The guideline provides an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. Topic areas discussed within the guideline include: staging, principles of pathology, surgery, endoscopic therapies, radiation therapy, combined modality therapy, chemotherapy, and follow-up.

Anal Carcinoma, Version 1.2016

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with anal carcinoma. Risk factors are discussed and recommendations are provided on risk reduction including HIV immunization, work up, management, and follow-up care. Treatment options are reviewed, with specific recommendations provided for primary treatment of: non-metastatic anal carcinoma, anal canal cancer, and anal margin cancer, as well as treatment for metastatic cancer and for locally progressive or recurrent anal carcinoma. Special considerations are made regarding treatment of anal cancer in patients with HIV/AIDS.

SCENIC International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease

Year: 2015
AGREE II score: Available
Developer organization: American Society for Gastrointestinal Endoscopy
A clinical practice guideline for the surveillance and management of patients with dysplasia in inflammatory bowel disease at risk of developing colorectal cancer. The guideline examines appropriate colonoscopy procedures, predominantly chromoendoscopy, and management through the resection of lesions. Outcomes of interest include increased surveillance and detection through high definition colonoscopies.

ACG Clinical Guideline: Epidemiology, Risk Factors, Patterns of Presentation, Diagnosis, and Management of Colon Ischemia (CI)

Year: 2015
AGREE II score: Unavailable
Developer organization: American College of Gastroenterology
A clinical practice guideline for the screening, diagnosis, and management of colon ischemia associated with colorectal cancer. The guideline examines appropriate CT or MRI imaging, colonoscopic diagnosis, and severity-based treatments including surgical intervention and antimicrobials. Outcomes of interest include decreased bacterial translocations and improved assessment of surgical risk.

Panitumumab And Cetuximab Toxicity Management Guidelines

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with advanced colorectal cancer. The guideline reviews the safe administration of Panitumumab or Cetuximab (anti-EGFR therapy). Monitoring and treatment of adverse treatment effects are reviewed, including cutaneous toxicities, diarrhea, hypomagnesemia, fatigue, asthenia, lethargy, or malaise, hypersensitivity reactions, and interstitial lung disease.

First-Line Treatment of HER2/neu Positive Locally Advanced, Recurrent or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction with Trastuzumab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with human epidermal growth factor receptor 2 (HER2)/neu positive locally advanced, recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction. The guideline examines the use of trastuzumab in conjunction with cisplatin and fluorouracil or capecitabine as a first-line treatment. Outcomes of interest include progression-free and overall survival.

The Role of Endoscopy in Ampullary and Duodenal Adenomas

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
This is a clinical practice guideline for the use of endoscopic approaches in the evaluation and treatment of ampullary adenomas. The guideline discusses evaluation of ampullary lesions before endoscopic therapy, the role of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) in assessment, and endoscopic resection. The role of EUS in management of duodenal adenomas is also examined. Adverse events and post-procedural care and surveillance are also addressed.

Recommendations for Laparoscopic Liver Resection: A Report from the Second International Consensus Conference Held in Morioka

Year: 2015
AGREE II score: Available
Developer organization: Second International Consensus Conference on Laparoscopic Liver Resections
A clinical practice guideline for laparoscopic liver resection. The guideline examines best practices for major and minor resections, including approaches, surgical safety, and potential adverse events. Outcomes of interest include operative mortality, postoperative complications, length of stay, and overall survival.

Effective Use of Advanced Practice Nurses in the Delivery of Adult Cancer Services in Ontario

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Ontario
This guideline provides recommendations on the use of advanced practice nurses (APNs) to optimize patient, provider, and health system outcomes across the cancer care continuum. Specifically, the guideline reviews patient populations and situations (types of needs, practice settings, phase of the cancer care continuum) for which APN roles have demonstrated equivalent or improved outcomes, or reduced harms in cancer care. Outcomes of interest include quality of life, physical, functional, psychosocial, and mental health, as well as morbidity, mortality, symptom management, patient and provider satisfaction, health care utilization, costs, and quality of care.

ACG Clinical Guideline: Primary Sclerosing Cholangitis

Year: 2015
AGREE II score: Unavailable
Developer organization: American College of Gastroenterology
A clinical practice guideline for the diagnosis and management of primary sclerosing cholangitis and possible development of bile duct and colon cancers. The guideline examines diagnosis through biochemical tests, autoantibodies and imaging as well as the lack of established medical treatments. Outcomes of interest include improved jaundice, reduced hospitalizations, and improved recommendations for reducing colonic malignancy risks.

ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus

Year: 2015
AGREE II score: Unavailable
Developer organization: American College of Gastroenterology
This is a clinical practice guideline for the diagnosis and management of Barrett's Esophagus (BE). The purpose of this guideline is to review the definition and epidemiology of BE, available screening modalities for BE detection, rationale and methods for surveillance, and available treatment modalities including medical, endoscopic, and surgical techniques. These 2015 guidelines differ markedly from their 2008 predecessor in several areas including: the expanded use of endoscopic ablative therapy, further refinement of screening recommendations, and a better understanding of the impact of gender and anthropomorphics on risk.

Tobacco Screening And Treatment For Adult Cancer Patients

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults (aged 18 and older) at any phase of the cancer care continuum regardless of cancer type, stage (including metastatic) or treatment plan, with some components of the guideline also applicable to the patient's family and/or caregivers. The guideline provides recommendations on implementation of the brief tobacco intervention, using the evidence-based 5 A’s model (ASK, ADVISE, ASSESS, ASSIST, ARRANGE) which includes screening, education and assessment, treatment plan, and referral, monitoring, and follow-up. Clinical considerations and contraindications of treatment options for cancer patients are discussed including nicotine replace therapy (NRT), bupropion, varenicline, and e-cigarettes. The impact of tobacco use on cancer treatment is also reviewed with a specific focus on erlotinib and irinotecan.

Thyroid Carcinoma, Version 2.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the diagnosis, staging, and treatment of thyroid carcinoma. Recommendations are stratified by histologic type, namely papillary, follicular, Hürthle cell, medullary, and anaplastic. Primary treatment options and assessment and management after initial treatment is reviewed. Recurrent or persistent disease is also discussed.

Esophageal and Esophagogastric Junction Cancers, Version 3.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations on esophageal and esophagogastric junction (EGJ) cancers, including: a review of hereditary cancer predisposition syndromes associated with increased risk for esophageal and EGJ cancers, staging and pathology, imaging, and treatment including surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies. Surveillance, management of metastatic, or recurrent cancer, and best supportive care are also discussed. Special topics of interest include treatment and surveillance options for patients with Barrett's esophagus, and suggested strategies to help alleviate the current problems associated with leucovorin shortage.

Somatostatin Analogues for the Management of Neuroendocrine Tumours

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This clinical practice guideline looks at the use of somatostatin analogues in management of neuroendocrine tumours. Topics reviewed include the use of somatostatin analogues for management of secretory syndromes as a result of tumours, the effectiveness in use for delaying tumour progression, and effectiveness in use for management of carcinoid heart disease. Otreotide is looked at for effectiveness in management of symptoms secondary to elevated calcitonin in medullary thyroid carcinoma. Outcomes of interest include treatment response, survival, and adverse events.

Oncogenetic Testing and Follow-up for Women With Familial Breast/Ovarian Cancer, Li-Fraumeni Syndrome and Cowden Syndrome

Year: 2015
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for adult women (18 years and older) either without breast cancer or with a recent diagnosis of breast cancer, who have a family history of breast, ovarian or a related cancer; the guideline also provides recommendations for men affected by male breast cancer. The guideline discusses oncogenetic testing aspects of breast cancer and ovarian, specifically hereditary breast cancer, the Li-Fraumeni syndrome, and the Cowden syndrome. Topics include criteria and indications for genetic testing, tests for which genes have clinical utility, and appropriate follow-up depending on results and family history.

The Role of Endoscopy in the Management of Premalignant and Malignant Conditions of the Stomach

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
This clinical practice guideline discusses the use of endoscopy in patients with malignant and premalignant conditions of the stomach including gastric polyps, gastric intestinal metaplasia (GIM), pernicious anemia, gastric carcinoid tumours, adenocarcinoma, mucosa-associated lymphoid tissue (MALT) lymphoma, and GI stromal tumours (GISTs). Surveillance endoscopy, staging ultrasound, biopsy, polypectomy, resection (surgical and endoscopic), and open gastrojejunostomy are discussed. Outcomes of interest include risk factors for dysplasia and gastric cancer, as well as survival rate, accuracy of staging techniques, and treatment complication rate.

Third-Line Treatment of Stage IV or Advanced, Unresectable Colorectal Carcinoma with Cetuximab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with stage IV or advanced, unresectable colorectal carcinoma. The guideline examines the use of cetuximab as a third-line therapy once other therapies, including fluoropyrimidines, oxaliplatin, or irinotecan, had been tried or when patients are intolerant to other options. Outcomes of interest include progression-free and overall survival.

Imatinib Mesylate (Gleevec™) for the Treatment of Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours: A Clinical Practice Guideline

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours. The guideline states that unresectable or metastatic gastrointestinal stromal tumours are often resistant to traditional methods of treatment like conventional chemotherapy. As such, the guideline focuses on the benefits and harms of imatinib mesylate as a form of treatment. The guideline therefore considers whether treatment with imatinib mesylate has a benefit in terms of tumour response, disease progression, survival or quality of life.

Australian Clinical Practice Guidelines for the Diagnosis and Management of Barrett’s Esophagus and Early Esophageal Adenocarcinoma

Year: 2015
AGREE II score: Available
Developer organization: Cancer Council Australia
This is a clinical practice guideline for patients with Barrett's esophagus (BE) without dysplasia and BE with dysplasia and/or early esophageal adenocarcinoma (EAC). Topics of discussion include: endoscopic and histological definitions of BE and early EAC; prevalence, incidence, natural history, and risk factors for BE and early EAC; and management of BE and early EAC, including modification of lifestyle factors, screening, surveillance, and medical, endoscopic, and surgical interventions.

JGES Guidelines for Colorectal Endoscopic Submucosal Dissection/Endoscopic Mucosal Resection

Year: 2015
AGREE II score: Unavailable
Developer organization: Japan Gastroenterological Endoscopy Society
A clinical practice guideline for the use of colorectal endoscopic submucosal dissection and endoscopic mucosal resection in patients with colorectal cancer. The guideline examines diagnostic indications, perioperative diagnosis, treatment techniques, and postoperative care. Outcomes of interest include recurrence, curability, and delayed bleeding/perforation.

Clinical Practice Guidelines for the Management of Biliary Tract Cancers 2015: the 2nd English Edition

Year: 2015
AGREE II score: Unavailable
Developer organization: Japanese Society of Hepato-Biliary-Pancreatic Surgery
This is a clinical practice guideline for the diagnosis and management of biliary tract cancers. The guidelines consist of algorithms that outline diagnosis and treatment followed by clinical questions regarding seven topics: prophylactic treatment, diagnosis, biliary drainage, surgical treatment, chemotherapy, radiation therapy, and pathology. Recommendations are therefore drawn from these clinical questions, and include recommendations as to what the first step in the diagnosis of the biliary tract cancers is, what the appropriate procedure for preoperative biliary drainage is and when it should be performed, and whether radiation therapy is useful for patients with unresectable biliary tract cancer.

Merkel Cell Carcinoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults over the age of 18 years with Merkel cell carcinoma of the skin. The guideline provides recommendations on staging and work-up, treatment options including surgery, radiation, and chemotherapy, and follow-up care. The guideline also provides recommendations on management of recurrences, and reviews sentinel lymph node biopsy protocol.

American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Asymptomatic Neoplastic Pancreatic Cysts

Year: 2015
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adults with pancreatic cysts. The guideline evaluates the evidence for diagnosing and managing pancreatic cysts. Important aspects discussed in the guideline include the taking of a detailed patient history, the use of imaging, and surgery. Outcomes of interest include the prevention of mortality from cystadenocarcinoma, the appropriateness of surgical intervention, and the progression of malignancy.

Colorectal Cancer Screening, Version 1.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients at average or increased risk of developing sporadic colorectal cancer (patients with high risk colorectal cancer syndromes are not discussed). The guideline discusses risk assessment and provides recommendations for screening modality and schedule stratified by risk. Patients with increased risk include those with a personal history of adenomatous or sessile serrated polyps, colorectal cancer, inflammatory bowel disease, and/or positive family history of colorectal cancer. Screening tests include colonoscopy, flexible sigmoidoscopy computed tomographic colonography, and fecal-based screening.

Suspected Cancer: Recognition and Referral

Year: 2015
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for patients of all age groups suspected of having cancers including lung and pleural, upper gastro-intestinal, lower gastrointestinal, breast, gynecological, urological, skin, head and neck, brain and central nervous system, haematological, sarcomas, and childhood cancers. Recommendations are provided on recognition and referral or investigations of cancer in primary care. Outcomes of interest include quality of life, sensitivity and specificity of diagnostic tests and signs/symptoms, positive and negative predictive values of diagnostic tests and signs/symptoms, and cost effectiveness.

Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society of Colon and Rectal Surgeons
This is a clinical practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. The guideline outlines different surveillance schedules, and offers recommendations for surveillance based on factors including: underlying risk for recurrence, patient comorbidity, and the ability to tolerate major surgery to resect recurrent disease or palliative chemotherapy, performance status, physiologic age, preference, and compliance.

The Role of Endoscopy in Inflammatory Bowel Disease

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
This clinical practice guideline discusses the use of endoscopy for the evaluation and management of inflammatory bowel disease (IBD), with a review of endoscopic approaches for general management of IBD and recommendations for screening and surveillance of colorectal cancer. Timing of screening colonoscopy and surveillance intervals are reviewed, and surveillance procedures are discussed with comparisons made between random biopsies, white light biopsy, and surface chromoendoscopy. The guideline also provides recommendations on the management of abnormal findings including endoscopically visible lesions and dysplasia. Additional topics of interest include pouch surveillance and stricture evaluation and dilation.

ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy

Year: 2015
AGREE II score: Available
Developer organization: American College of Radiology
A clinical practice guideline for the radiologic management of hepatic malignancies. The guideline examines disease variants and potential treatment, including transplantation, ablative therapies, and systemic therapies. Outcomes of interest include long-term survival and reduced toxicity.

First-Line Treatment of Metastatic Pancreatic Adenocarcinoma with FOLFIRINOX

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with metastatic pancreatic adenocarcinoma. The guideline examines the use of folfirinox - a combination of fluorouracil, oxaliplatin, leucovorin and irinotecan - as a first-line treatment. Outcomes of interest include progression-free and overall survival.

The Role of Deep Enteroscopy in the Management of Small-bowel Disorders

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
This clinical practice guideline discusses the use of deep enteroscopy (DE) in the management of small-bowel disorders including diagnosis and therapeutic intervention of small-bowel tumours. The guideline compares different DE techniques including double-balloon enteroscope (DBE) single-balloon enteroscope (SBE), and the Endo-Ease Discovery SB (SE). Safety and efficacy are the primary outcomes of interest.

Evidence-Based Clinical Practice Guidelines for Management of Colorectal Polyps

Year: 2015
AGREE II score: Available
Developer organization: The Japanese Society of Gastroenterology
This is a clinical practice guideline for management of colorectal polyps. In recognizing an increase in the morbidity of colorectal polyp in Japan, this guideline seeks to provide recommendations for endoscopic management and surveillance after treatment. Guideline developers created a number of clinical questions and statements for the current concept and diagnosis/treatment of various colorectal polyps including epidemiology, screening, pathophysiology, definition and classification, diagnosis, treatment/management, practical treatment, complications and surveillance after treatment, and other colorectal lesions (submucosal tumors, non-neoplastic polyps, polyposis, hereditary tumors, ulcerative colitis-associated tumor/carcinoma).

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for Treatment of Colorectal Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Japanese Society for Cancer of the Colon and Rectum (JSCCR)
This is a clinical practice guideline for the treatment of colorectal cancer. The overarching aim of the guideline is to provide standard treatment strategies for colorectal cancer, to eliminate treatment disparities among institutions, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding among health-care professionals and patients. Issues addressed include: surgical treatment, treatment strategies after resection, as well as palliative care options.

Systemic Therapy for Well and Moderately Differentiated Unresectable Pancreatic Neuroendocrine Tumours

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients diagnosed with well or moderately differentiated (grade 1 or 2) pancreatic neuroendocrine tumours (PNETs). The guideline reviews the use of targeted therapies for PNETs including sunitinib malate, everolimus, and combination treatment with capecitabine/temozolomide. Recommendations are provided on use, dose, and schedule. Outcomes of interest include progression free survival (versus placebo) and toxicity.

Adenocarcinoma of the Pancreas

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with adenocarcinoma of the pancreas. The guideline discusses diagnostic workup, treatment options for potentially curable adenocarcinoma of the pancreas, and management of unresectable adenocarcinoma of the pancreas including locally advanced and metastatic disease. Surgical and first and second line systemic treatment options are discussed. Toxicity of systemic therapy regimes is also reviewed.

Oncogenetic Testing for Persons With Hereditary Endocrine Cancer Syndromes

Year: 2015
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
This clinical practice guideline discusses genetic testing for patients diagnosed with or suspected of having hereditary endocrine cancer syndromes, specifically multiple endocrine neoplasia type 2 (MEN2), multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau (VHL) syndrome, and paraganglioma and phaeochromocytoma. Indications for genetic testing of relatives of patients is also reviewed. Genetic testing for Succinate Dehydrogenase B, C and D (SDHB, SDHC, SDHD), menin, VHL and RET mutations are discussed. Outcomes of interest include diagnostic accuracy, health outcomes, and psychosocial outcomes.

ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

Year: 2015
AGREE II score: Unavailable
Developer organization: American College of Gastroenterology
This is a clinical practice guideline for patients diagnosed with or at risk of hereditary gastrointestinal cancer syndromes including lynch syndrome, familial adenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP), MUTYH-associated polyposis (MAP), Peutz–Jeghers syndrome, juvenile polyposis syndrome, Cowden syndrome, serrated (hyperplastic) polyposis syndrome, hereditary pancreatic cancer, and hereditary gastric cancer. The guideline reviews initial assessment, genetic testing for a germline mutation when indicated, pre- and post-test genetic counselling, and management of patients who meet clinical criteria for a syndrome as well as those with identified pathogenic germline mutations. Outcomes of interest include cancer risk, quality of life, and survival benefit from surveillance.

ACR Appropriateness Criteria Recurrent Rectal Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: American College of Radiology
This is a clinical practice guideline for patients with recurrent rectal cancer. The guideline examines the appropriateness of treatment strategies including reirradiation, intraoperative radiotherapy, permanent seed implants, stereotactic body radiotherapy, and particle therapy. The effectiveness or radiation versus chemoradiation and the importance of preoperative or definitive radiation in these patients is also considered.

Guidelines for the Diagnosis and Management of Intrahepatic Cholangiocarcinoma

Year: 2014
AGREE II score: Unavailable
Developer organization: International Liver Cancer Association (ILCA)
This is a clinical practice guideline for patients diagnosed with or suspected of having intrahepatic cholangiocarcinoma (iCCA). The guideline discusses iCCA incidence, risk factors, and molecular pathogenesis, and provides recommendations on diagnostic assessment, staging, and management. Treatment options including surgery, liver transplantation, loco-regional therapy, and systemic therapy are discussed. Outcomes of interest include survival (recurrence-free, median, three-year, five-year), quality of life, and toxicity.

Advanced Imaging for Detection and Differentiation of Colorectal Neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Year: 2014
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
A clinical practice guideline for patients with suspected colorectal neoplasia. The guideline examines diagnosis and differentiation through endoscopic imaging, including virtual and conventional methods. Outcomes of interest include improved lesion characterization and improved detection of hereditary syndromes.

British Thyroid Association Guidelines for the Management of Thyroid Cancer

Year: 2014
AGREE II score: Available
Developer organization: British Thyroid Association
A clinical practice guideline for the management of patients with differentiated and medullary thyroid cancer. The guideline examines the management of thyroid cancer from diagnosis to follow-up, with specific focus on radioiodine remnant ablation and appropriate post-treatment follow-up. Outcomes of influence include improved outcomes in total thyroidectomy and improved personalised decision making.

Provincial Hepatocellular Cancer Treatment Guidelines

Year: 2014
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for adult and pediatric hepatocellular cancer patients. The guideline examines assessment and treatment for both curative and non-curative therapies. Outcomes of interest include clarified follow-up timing and early involvement of supportive care.

Provincial Biliary Tract & Gall Bladder Cancer Treatment Guidelines

Year: 2014
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with biliary tract and gall bladder cancers. The guidelines examines assessment and treatment based on disease staging or re-staging, primarily thought chemotherapy or surgery. Outcomes of interest include improved nutritional supplementation and reduced need for follow-up imaging.

Saudi Oncology Society Clinical Management Guideline Series: Esophageal Cancer 2014

Year: 2014
AGREE II score: Unavailable
Developer organization: Saudi Oncology Society
A clinical practice guideline for the management of esophageal cancer. The guideline examines pre-treatment workup, staging, and treatment, primarily through surgical methods. Outcomes of interest include more complete esophageal dissection and clarified options for palliative care.

Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline

Year: 2014
AGREE II score: Unavailable
Developer organization: The Endocrine Society
This is a clinical practice guideline for patients suspected of having or diagnosed with pheochromocytoma and paraganglioma (PPGL). Recommendations are provided for diagnostic biochemical testing, imaging studies, genetic testing, perioperative medical management, and surgery. The guideline also discusses personalized management of PPGLs with recognition of the distinct genotype-phenotype presentations of hereditary PPGLs. Outcomes of interest include sensitivity of diagnostic tests, rates of metastasis or recurrence after treatment, and peri- and post-operative complications.

The Management of Thymoma: A Systematic Review and Practice Guideline

Year: 2014
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
A clinical practice guideline for adult patients with locally advanced, unresectable, and recurrent thymoma. The guideline examines treatment options, primarily surgical resection, as well as preferred approaches to therapy. Outcomes of interest include ranged overall survival, and improved recommendations for patients medically unfit for surgery.

Systemic Therapy for Advanced Gastric Cancer

Year: 2014
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with advanced (non-resectable; either locally advanced or metastatic) adenocarcinoma of the gastroesophageal junction (but not with squamous cell carcinoma). The guideline provides recommendations on chemotherapy treatment with review of chemotherapy agents by class, as well as comparison of 5-fluorouracil (CIV)/epirubicin/cisplatin regimens vs. other chemotherapy. The guideline also discusses the contribution of targeted therapies. Outcomes of interest including overall survival, objective response rate (complete plus partial response), time to disease progression, adverse effects, and quality of life.

Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients

Year: 2014
AGREE II score: Available
Developer organization: Cancer Care Ontario
A clinical practice guideline for adult patients with unresectable or metastatic/recurrent gastrointestinal stromal tumours that have become resistant or intolerant to imatinib mesylate. The guideline examines the efficacy of sunitinib malate as an alternative, and reviews what dosing regimens could be observed. Outcomes of interest include partial response, but no difference in quality of life.

British HIV Association Guidelines for HIV-Associated Malignancies 2014

Year: 2014
AGREE II score: Available
Developer organization: British HIV Association
This is a clinical practice guideline for the diagnosis and treatment of cancer and associated malignancies in adult patients with HIV. The guideline examines the most common HIV associated cancers, Kaposi sarcoma, high grade B-cell non-Hodgkin lymphoma and invasive cervical cancer, as well as a number of other cancers with higher risk profiles in HIV patients. Outcomes of interest include improved treatment options in consideration of HAART and increased prophylactic options in low-risk patients, specifically with regards to lifestyle changes and vaccinations.

Optimization of Preoperative Assessment in Patients Diagnosed with Rectal Cancer

Year: 2014
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients with rectal cancer who are newly diagnosed. The guideline provides recommendations on investigations to assess for metastases and synchronous lesions, imaging for local staging, optimal MRI protocol and criteria for local staging, optimal MRI criteria to select patients for neoadjuvant therapy, the role of multidisciplinary cancer conferences and the role of restaging MRI after neoadjuvant therapy.

Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines

Year: 2014
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline endorsement for people at risk for hereditary colorectal cancer (CRC) syndromes. The guideline provides recommendations on prevention, screening, genetics, treatment, and management. Topics of interest addressed in the guideline include: tumour testing for DNA mismatch repair (MMR) deficiency, genetic testing for Lynch syndrome, as well as follow-up recommendations in mutation carriers.

MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

Year: 2014
AGREE II score: Available
Developer organization: Multinational Association Supportive Care in Cancer
A clinical practice guideline for patients undergoing therapy for head and neck and gastrointestinal cancers. The guideline examines the prevention and management of mucositis through multiple medical and alternative interventions. Outcomes of interest include lack of benefit with sucralfate and improved basic oral care.

Provincial Pancreatic Cancer Treatment Guidelines

Year: 2014
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with pancreatic cancer. The guideline examines assessment and treatment, primarily through radical resections including Whipple procedures. Outcomes of interest include reduced chemotherapy toxicity with gemcitabine and improved follow-up procedures.

Provincial Gastric and Gastro-Esophageal Junction Cancer Treatment Guidelines

Year: 2014
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for gastric and gastro-esophageal junction cancer patients. The guidelines examines assessment by a multidisciplinary team, and treatment options including gastrectomy and endomucosal resection. Outcomes of interest include increased survival through combination therapy and potential benefit from biomarker targeted therapies.

Saudi Oncology Society Clinical Management Guideline Series: Anal Canal Cancer 2014

Year: 2014
AGREE II score: Unavailable
Developer organization: Saudi Oncology Society
This is a clinical practice guideline for patients with anal canal cancer. The guideline provides recommendations for the pre-treatment evaluation, staging, and treatment options. Recommendations include a consideration of the appropriateness of x-ray, CT, and MRI; the American Joint Commission on Cancer pathological staging system; as well as resection, chemotherapy and radiotherapy.

Timing and Extent of Thyroid Surgery for Gene Carriers of Hereditary C Cell Disease – A Consensus Statement of the European Society of Endocrine Surgeons (ESES)

Year: 2014
AGREE II score: Unavailable
Developer organization: European Society of Endocrine Surgeons (ESES)
This is a clinical practice guideline for patients who are Rearranged during Transfection (RET) proto-oncogene mutation carriers. The guideline provides recommendations on the timing and extent of thyroid surgery. Recommendations are stratified by patient risk with considerations made to genetic characteristics, patient age at diagnosis, and calcitonin levels at the time of decision making. Postoperative management and follow-up is also discussed. Outcomes of interest include risk of metastasis and risks of extended surgery (including permanent hypoparathyroidism and permanent paralysis of the recurrent laryngeal nerve).

Diagnosis, Treatment, and Follow-up of Medullary Thyroid Carcinoma: Recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism

Year: 2014
AGREE II score: Unavailable
Developer organization: Brazilian Society of Endocrinology and Metabolism
This is a clinical practice guideline for individuals with or suspected of having Medullary thyroid carcinoma (MTC). The guideline provides recommendations on diagnosis, surgical treatment, and follow-up care. The use of chemotherapy and/or radiotherapy in the management of individuals with metastatic MTC is also discussed. The appropriate use of RET proto-oncogene molecular testing during diagnostic assessment is discussed, and the potential value in the use of tyrosine-kinase inhibitors as a treatment option is reviewed. Outcomes of interest include survival rate (median, overall, 10-year, progression-free), sensitivity and specificity of diagnostic tests, cure rate, rate of remission, and recurrence rate.

Extended Pancreatectomy in Pancreatic Ductal Adenocarcinoma: Definition and Consensus of the International Study Group for Pancreatic Surgery (ISGPS)

Year: 2014
AGREE II score: Unavailable
Developer organization: International Study Group on Pancreatic Surgery (ISGPS)
This is a clinical practice guideline for ductal adenocarcinoma of the pancreas. The guideline provides recommendations for extended pancreatectomy. Related topics examined in this guideline include: resectability, perioperative morbidity and mortality, and prognosis.

Saudi Oncology Society Clinical Management Guideline Series: Pancreatic Cancer 2014

Year: 2014
AGREE II score: Unavailable
Developer organization: Saudi Oncology Society
This clinical practice guideline provides recommendations on pancreatic cancer management including pre-treatment evaluation, surgical pathology report requirements, staging classifications, assessment of resectability, and treatment. Pancreatico-duodenectomy, radiotherapy, chemoradiotherapy, and chemotherapy are discussed as treatment options depending on resectability. Management of metastatic pancreatic cancer and locally recurrent disease are included in this review.

Saudi Oncology Society Clinical Management Guideline Series: Colorectal Cancer 2014

Year: 2014
AGREE II score: Unavailable
Developer organization: Saudi Oncology Society
This is a clinical practice guideline for the pre-treatment evaluation, staging, and treatment of colorectal cancer. Topics addressed in the guideline include an overview of surgical pathology report requirements; as well as treatment options for clinically localized resectable colon cancer, clinically localized resectable rectal cancer, and locally advanced unresectable or metastatic colon or rectal cancer.

Saudi Oncology Society Clinical Management Guideline Series: Gastric Cancer 2014

Year: 2014
AGREE II score: Unavailable
Developer organization: Saudi Oncology Society
A clinical practice guideline for patients with esophagogastric junction tumour. The guideline examines staging, pre-treatment evaluation, treatment through surgery and adjuvant therapy, and basic follow-up. Important aspects include surgical pathology report requirements and post-operative management.

Definition of a Standard Lymphadenectomy in Surgery for Pancreatic Ductal Adenocarcinoma: A Consensus Statement by the International Study Group on Pancreatic Surgery (ISGPS)

Year: 2014
AGREE II score: Unavailable
Developer organization: International Study Group on Pancreatic Surgery (ISGPS)
This is a clinical practice guideline for patients with resectable pancreatic ductal adenocarcinoma. The guideline provides recommendations on pancreatoduodenectomy, with comparisons made to extended versus standard lymphadenectomy during surgery. Primary outcome of interest is survival benefit.

British Society of Gastroenterology Guidelines on the Diagnosis and Management of Barrett’s Oesophagus

Year: 2014
AGREE II score: Available
Developer organization: British Society of Gastroenterology
This is a clinical practice guideline for Barrett’s oesophagus and related early neoplasia. The guideline provides recommendations to guide patient management. The guideline addresses issues in Barrett’s oesophagus including: definition, screening and diagnosis, surveillance, pathological grading for dysplasia, management of dysplasia, and early cancer including training.

Borderline Resectable Pancreatic Cancer: A Consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)

Year: 2014
AGREE II score: Unavailable
Developer organization: International Study Group of Pancreatic Surgery (ISGPS)
This is a clinical practice guideline for pancreatic cancer. The guideline examines treatment options for borderline resectable pancreatic ductal adenocarcinoma (BRPC). Topics explored in this guideline include: operative exploration, resection in the case of involvement of the mesentericoportal venous axis, and regimens of neoadjuvant therapy.

Required Reports for Referrals

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on required reports for referrals for: breast, gastrointestinal (esophagus, stomach, colon-rectum, anus, pancreas, liver, biliary tract/gall bladder), genitourinary (testis, prostate, bladder), gynecology (endometrium, cervix, ovary, vulva & vagina), head and neck (parotid & submandibular gland, thyroid, mouth, palate, nasopharynx, oropharynx, hypopharynx, nose & antrum, ear), lung, lymphoma and leukemia, melanoma, musculoskeletal and sarcoma, neuro-oncology, primary unknown, and skin (basal cell & squamous cell carcinomas, mycosis fungoides – Sezary syndrome). The guideline provides recommendations on pathology reports, operative reports, laboratory reports, and imaging reports. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Early Detection of Cancer in AYAs

Year: 2014
AGREE II score: Available
Developer organization: Cancer Council Australia
This is a clinical practice guideline for the early detection of common cancers in adolescents and young adults aged between 15 and 24 years of age. The cancers covered include leukemia, lymphoma, brain tumours, soft tissue sarcoma, testicular cancer, thyroid cancer, and melanoma. The guideline discusses common signs and symptoms and provides recommendations on clinical assessment and referral. "Youth-friendly" communication between practitioner and patient is also discussed, and links for patient and practitioner resources are provided.

Anal Cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2014
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients diagnosed with or at risk of having anal cancer. The guideline outlines screening and prevention, diagnostic assessment and staging, treatment, and follow-up and surveillance. Special topics of interest include treatment of the elderly and personalized medicine. Management of advanced/metastatic disease is also discussed. Outcomes of interest include survival, recurrence rates and quality of life.

Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: American College of Gastroenterology
This is a clinical practice guideline for patients at risk for and affected with Lynch syndrome. The guideline examines appropriate provision of genetic testing and management of patients. Important aspects include: ways to assess individuals for the risk of colorectal cancer, tumour testing, algorithms for genetic evaluation of affected and at-risk family members of pedigrees with Lynch syndrome, and the provision of diagnosis and management strategies to health-care providers caring for these patients.

ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions

Year: 2014
AGREE II score: Unavailable
Developer organization: American College of Gastroenterology
A clinical practice guideline for the diagnosis and management of focal liver lesions, including hemangioma, focal nodular hyperplasia, hepatocellular adenoma, and hepatic cysts. The guideline examines diagnosis, including imaging characteristics, and treatment modalities. Outcomes of interest include a focus on local availability of expertise and resources, and improved 5-year survival through early detection.

Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer – Addendum to Clinical Guideline 131

Year: 2014
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
A clinical practice guideline for acute bowel obstruction caused by colorectal cancer and patients with early stage rectal cancer. The guideline examines the efficacy of stenting and bowel resection as an alternative to emergency procedures, and less invasive treatments, including transanal endoscopic microsurgery, as first-line treatment for early stage cancer. Outcomes of interest include reduced hospital stay and improved bowel function.

Metastatic Colorectal Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over 18 years of age with metastatic colorectal cancer. The guideline reviews surveillance and treatment options including surgery, radiotherapy, palliative chemotherapy and biological therapy. Outcomes of interest include survival (overall, progression-free), and toxicity.

Hepatocellular Carcinoma

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with hepatocellular carcinoma. The guideline provides recommendations on diagnostic assessment, staging, and management. Treatment options including resection, liver transplantation, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), transarterial chemo-embolization (TACE), transarterial radioembolization (TARE), sorafenib, and stereotactic body radiotherapy (SBRT) are reviewed.

Adenocarcinoma of the Pancreas

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over 18 years of age with pancreatic cancer. The guideline reviews diagnostic work-up, staging, and treatment options for both potentially curable and unresectable pancreatic cancer. Comparisons are made between FOLFIRINOX and gemcitabine chemotherapy regimes. Outcomes of interest include survival, adverse events, and response rate.

Provincial Esophageal and Gastro-Esophageal Junction Cancer Treatment Guidelines

Year: 2014
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with esophageal cancer and gastro-esophageal junction cancer. The guideline examines diagnostic assessment and proposed treatment based on cancer staging, with a focus on chemoradiation and surgical therapies. Outcomes of interest include improved recommendations for patients with good and poor performance.

Treatment of Borderline Resectable and Locally Advanced Pancreatic Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: Eastern Health
This is a clinical practice guideline for patients diagnosed with borderline resectable or locally advanced pancreatic cancer. The guideline reviews pre-treatment staging, therapeutic options including biliary decompression and neoadjuvant therapy, chemotherapy with and without gemcitabine, chemoradiation therapy (CRT), induction chemotherapy and CRT, and radiological re-evaluation. Outcomes of interest include survival (median, overall, progression-free), treatment toxicity, adverse events, and surgical resectability rates.

Neo-adjuvant Treatment of Stage II and Stage III Rectal Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: Eastern Health
This is a clinical practice guideline for patients with a pathological confirmed diagnosis of locally advanced rectal cancer following appropriate radiological staging investigations. The guideline reviews treatment options including chemoradiation regimes and timing (adjuvant vs neo-adjuvant). Treatment related toxicities are also discussed. Outcomes of interest include overall survival, local recurrence, tumour response, and toxicity (acute and chronic).

Colorectal Cancer Screening Clinical Practice Guideline

Year: 2014
AGREE II score: Available
Developer organization: Kaiser Permanente
This clinical practice guideline addresses colorectal cancer screening for asymptomatic adults, in the primary care setting. Risk factors and screening test effectiveness are discussed and recommendations are provided based on age and risk. Outcomes of interest include colon cancer incidence, morbidity, and mortality, as well as outcomes of screening intervention including test effectiveness and adverse effects.

Strategies of Sequential Therapies in Unresectable, Metastatic Colorectal Cancer Treated With Palliative Intent

Year: 2014
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients (18 years or older) with unresectable metastatic colorectal cancer. The guideline provides recommendations on sequential chemotherapy strategies for treatment with palliative intent. The cytotoxic agents discussed include initial fluoropyrimidine (5-FU or capecitabine) either alone or in combination, irinotecan and oxaliplatin. Outcomes of interest are overall survival, toxicity, and quality of life.

Gastrointestinal Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on gastrointestinal cancer, with sub-sections discussing the following tumour sites: anus, bile duct, colon, esophageal and esophagogastric junction, gallbladder, liver, neuroendocrine tumours, lymphoma, gastro-intestinal stromal tumours (GIST), pancreas, rectum, small bowel, and stomach. Important aspects discussed in the guideline include: screening, diagnostic and staging, surgical therapy, staging, follow up and surveillance, and considers different treatment options. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Colon Cancer: Diagnosis, Treatment and Follow-Up

Year: 2014
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for adult patients diagnosed with or suspected of having colon cancer. The guideline provides recommendations on diagnostic assessment and staging, pathology, treatment, and follow-up care. The use of KRAS mutational analysis and BRAF are reviewed, and N-RAS and MSI are discussed as predictors of treatment effectiveness. Comparisons are made between chemotherapy regimes, surgical techniques, and recovery programs. Outcomes of interest include sensitivity and specificity of diagnostic tests, survival (progression-free, overall), surgical outcomes (mortality, complications, readmissions, hospital stay, peri-procedural morality), and quality of life.

Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer

Year: 2014
AGREE II score: Available
Developer organization: US Multi-Society Task Force on Colorectal Cancer
A clinical practice guideline for adult and paediatric patients undergoing colonoscopies for cancer surveillance. The guideline examines appropriate bowel cleansing procedures, including dietary recommendations and salvage options. Outcomes of interest include improved OTC purgative prescription and greater use of low-volume agents.

Clinical Indications for Computed Tomographic Colonography: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline

Year: 2014
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
A clinical practice guideline for the use of computed tomographic colonography in patients with colorectal cancer. The guideline examines colorectal surveillance and polypectomy and their feasibility for patients with symptoms of colorectal cancers. Outcomes of interest include improvements over standard barium enemas and increased diagnostic sensitivity.

Italian Consensus Guidelines for the Diagnostic Work-up and Follow-up of Cystic Pancreatic Neoplasms

Year: 2014
AGREE II score: Available
Developer organization: Italian Association of Hospital Gastroenterologists and Endoscopists, AIGO
This clinical practice guideline provides recommendations on diagnostic assessment and follow-up for patients with cystic pancreatic neoplasms. Topics covered include indications for work-up, laboratory tests, serum markers, imaging and nuclear medicine, ultrasound/endoscopy, laboratory markers in cystic fluid, and pathology. Outcomes of interest include sensitivity and specificity, positive and negative predictive values, and accuracy of diagnostic/assessment procedures.

When to Perform a Pancreatoduodenectomy in the Absence of Positive Histology? A Consensus Statement by the International Study Group of Pancreatic Surgery

Year: 2014
AGREE II score: Unavailable
Developer organization: International Study Group of Pancreatic Surgery (ISGPS)
This is a clinical practice guideline for localized pancreatic head cancer. The guideline examines when to perform a pancreatoduodenectomy (PD) in the absence of positive histology. Other important aspects discussed in the guideline include: the issue of the preoperative biopsy, pancreatitis, and neuroendocrine neoplasms.

Consensus Guidelines for Enhanced Recovery after Gastrectomy: Enhanced Recovery After Surgery (ERAS) Society Recommendations

Year: 2014
AGREE II score: Unavailable
Developer organization: Enhanced Recovery After Surgery Group
This guideline reviews perioperative care for enhanced recovery after gastrectomy for cancer. Recommendations are provided on preoperative counselling and nutrition, surgical preparation, technique, and methods, analgesia and anaesthetic management, and postoperative care including management of fluid balance, urinary drainage, glycaemic control, and stimulation of bowel movement, among others.

Oncogenetic Testing for Lynch Syndrome and Familial Adenomatous Polyposis

Year: 2014
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for patients with colorectal cancer or for patients who are otherwise at risk of Lynch syndrome or familial adenomatous polyposis (FAP). The guideline provides recommendations on the identification and referral of patients to genetic centres for counselling, and discusses appropriate follow-up screening for Lynch syndrome and FAP. The use of Microsatellite instability (MSI) as both a predictor of treatment effectiveness and a predictor of Lynch syndrome is reviewed, with MSI compared to immunohistochemistry when screening for Lynch syndrome.

Stages II and III Colorectal Cancer Surveillance

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over the age of 18 years with stage II or III colorectal cancer. The guideline discusses follow-up care and provides recommendations regarding the timing and appropriateness of surveillance tests/procedures including CEA testing, colonoscopy, PET scans and CT scans. The guideline also discusses how physicians can educate patients about adopting healthy lifestyle behaviours to improve survival outcomes.

Management of Patients With Early Esophageal Cancer, Dysplastic and Non-Dysplastic Barrett’s Esophagus

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for the management of patients with early esophageal cancer, dysplastic and non-dysplastic Barrett's esophagus. This guideline examines treatment options and considers in what clinical situations endoscopic therapy is the most appropriate treatment. Treatment options explored and discussed include: endoscopic mucosal resection, radiofrequency ablation, photodynamic therapy, argon plasma coagulation, and multipolar electrocoagulation.

Self-expandable Metal Stents for Obstructing Colonic and Extracolonic Cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Year: 2014
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy
A clinical practice guideline for patients with malignant colonic obstruction and colorectal cancer. The guideline examines colonic self-expandable metal stent placement in prophylactic, elective, emergency, and palliative surgeries. Outcomes of interest include reduced colonic perforation and reduced mortality.

Practice Parameters for the Surgical Treatment of Ulcerative Colitis

Year: 2014
AGREE II score: Unavailable
Developer organization: American Society of Colon and Rectal Surgeons
This is a clinical practice guideline outlining surgical treatment options for patients with ulcerative colitis. The guideline examines indications for surgery, with a specific focus on the intractability of ulcerative colitis, as well as surgical and postoperative management. The guideline also provides recommendations for cancer screening by endoscopy for patients with long-standing ulcerative colitis. Outcomes of interest include improvements in quality of life and potential curative measures.

Continuous versus Intermittent Chemotherapy Strategies in Inoperable, Advanced Colorectal Cancer

Year: 2014
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients (18 years or older) with inoperable, advanced (Stage IV) colorectal cancer. The guideline provides recommendations on the use of intermittent systemic treatment strategies. Outcomes of interest include overall response rate, survival (overall, progression-free, failure free), toxicity, and quality of life.

Guidelines for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs)

Year: 2014
AGREE II score: Unavailable
Developer organization: Clinical Oncological Society of Australia
A clinical practice guideline for patients with gastroenteropancreatic neuroendocrine tumours (GEP NETs). The guideline examines multiple treatment options, including surgery and systemic therapies. Outcomes of interest include treatment response, median time to progression, and survival. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of May 1, 2014.

Recommendations for Bowel Obstruction With Peritoneal Carcinomatosis

Year: 2014
AGREE II score: Available
Developer organization: French Society for Palliative Care
This is a clinical practice guideline for patients who have bowel obstruction with advanced peritoneal carcinomatosis for which complete cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion are no longer relevant. The guideline provides recommendations on clinical assessment and treatment options for relieving intestinal obstruction or its symptoms. Treatment/management options include surgery, steroids, stents, nasogastric tubes (NGT's) and venting gastronomy, antisecretory drugs, and antiemetic management. Outcomes of interest include complication rate of surgical management (e.g. obstruction, perforation), morbi-mortality rates from surgery, and quality of life.

European Experts Consensus Statement on Cystic Tumours of the Pancreas

Year: 2013
AGREE II score: Unavailable
Developer organization: European Study Group on Cystic Tumours of the Pancreas
A clinical practice guideline for patients with cystic tumours of the pancreas. The guideline examines the diagnosis and management of pancreatic tumours, including assessment of biopsy and surgical assessment. Outcomes of interest include improved diagnostic imaging and improved follow-up.

Pre-operative Staging of Primary Rectal Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Eastern Health
This clinical practice guideline provides recommendations on optimal staging investigations for patients with newly diagnosed primary cancer of the rectum. Diagnostic procedures are reviewed including digital rectal examination (DRE), rigid proctoscopy, total colonoscopy, Intraluminal Endoscopic Ultrasound (EUS), Magnetic Resonance Imaging (MRI), Computed Tomography (CT) , and Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/CT Scanning. Outcomes of interest include test sensitivity and specificity.

2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: European Thyroid Association
This is a clinical practice guideline for patients with metastatic medullary thyroid cancer. The guideline reviews diagnostic assessment, local treatment modalities, and systemic treatment (chemotherapy and clinical trials). It also discusses symptoms, evaluation, and treatment of hormonally active metastases. Outcomes of interest include survival, rate of progression, effectiveness of treatment, and toxicity.

Post-Polypectomy Colonoscopy Surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Year: 2013
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This clinical practice guideline reviews risk stratification following the removal of precancerous neoplastic lesions and provides recommendations for timing of endoscopic surveillance. Outcomes of interest include short- and long-term risk of future development of advanced neoplasia, incidence and mortality of metachronous advanced lesions, and accuracy of screening procedures.

The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology

Year: 2013
AGREE II score: Available
Developer organization: American Society for Colposcopy and Cervical Pathology
A clinical practice guideline for patients with, or suspected of having, HPV associated lesions of the lower anogenital tract. The guideline examines appropriate terminology for cancers of the anogenital region and provides a diagnostic and histopathologic nomenclature system for use in clinical settings. Outcomes of interest include clarified margins for squamous cells and lesions in terms of both regional definition and staging.

The Role of Endoscopy in the Evaluation and Treatment of Patients with Biliary Neoplasia

Year: 2013
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
This is a clinical practice guideline for adult patients with suspected biliary neoplasia. The guideline reviews evaluation and treatment options of biliary neoplasia including cholangiocarcinoma, gallbladder polyps, and adenocarcinoma of the gallbladder. Recommendations are provided for radiologic imaging and endoscopic approaches. Outcomes of interest include sensitivity, specificity of diagnostic procedures, and safety and effectiveness of endoscopic procedures.

Guideline for Colonoscopy Quality Assurance in Ontario

Year: 2013
AGREE II score: Available
Developer organization: Cancer Care Ontario
A professional guideline for colonoscopy training as part of fecal occult blood test based colorectal cancer screening. The guideline examines training, competency maintenance, and quality assurance measures for colonoscopies and related patient assessment procedures. Outcomes of interest include improved auditable outcomes and clearer pre-assessment standards.

Preoperative or Postoperative Therapy for Resectable Esophageal Cancer

Year: 2013
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with resectable, operable, and potentially curable thoracic (lower two thirds of esophagus) esophageal cancer for whom surgery is considered appropriate. The guideline compares treatment regimes including pre- and postoperative chemotherapy and/or radiotherapy versus surgery alone. Outcomes of interest include treatment related mortality, local control, survival benefits, and adverse effects.

Gastric Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over the age of 18 with gastric cancer. The guideline discusses diagnostic work-up, staging, and treatment recommendations. Outcomes of interest include survival (overall and five-year progression-free), and side effects of therapy.

International Cancer of the Pancreas Screening (CAPS) Consortium Summit on the Management of Patients With Increased Risk for Familial Pancreatic Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: International Cancer of the Pancreas Screening (CAPS) Consortium
This is a clinical practice guideline for patients with an increased risk of familial pancreatic cancer. The guideline discusses risk stratification and provides recommendations on screening, surveillance and management of high-risk individuals. Topics of discussion include a comparison of screening methods, and threshold criteria for surgery for patients with lesions identified during screening.

Magnetic Resonance Imaging for the Clinical Management of Rectal Cancer Patients: Recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Consensus Meeting

Year: 2013
AGREE II score: Unavailable
Developer organization: European Society of Gastrointestinal and Abdominal Radiology (ESGAR)
This clinical practice guideline reviews the use of MRI for primary clinical staging or restaging of rectal cancer. The guideline provides recommendations on MRI requirements and sequences, criteria for MRI assessment, and MRI reporting. Imaging techniques including endorectal ultrasound, computed tomography (CT), and positron emission tomography (PET) are also discussed.

2013 European Thyroid Association Guidelines for Cervical Ultrasound Scan and Ultrasound-Guided Techniques in the Postoperative Management of Patients with Thyroid Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: European Thyroid Association
This clinical practice guideline examines the use of cervical ultrasound scanning (US) in the postoperative management of patients with differentiated thyroid cancer of follicular origin. Topics of interest include recommendations on US procedure including fine needle aspiration technique, differentiation of benign and pathological US patterns, and indications for cervical ultrasound, US-FNA, and in situ biological marker assessment. New methods for preoperative localization of cervical recurrence and alternatives to surgical treatment of cervical recurrence are also discussed. Outcomes of interest include sensitivity, specificity, predictive value, and accuracy of ultrasound scanning.

Management of the Malignant Colorectal Polyp: ACPGBI Position Statement

Year: 2013
AGREE II score: Unavailable
Developer organization: Association of Coloproctology of Great Britain and Ireland
This is a clinical practice guideline for patients with a malignant polyp. The guideline reviews topics such as colonoscopy and endoscopic technique for the removal of large adenomas, the histopathology of adenomas and polypoid carcinomas, how prognostic indicators influence the risk of residual cancer in the bowel wall or lymph nodes, and the likelihood of recurrence if additional treatment is not taken. As well, the benefits and harms of endoscopic resection are reviewed, and the role of endoscopic and radiological imaging in the assessment and follow up of malignant polyps is discussed. Outcomes of interest include risk of post-surgical morbidity and mortality, risk of recurrence, disease-specific survival, and nodal metastasis.

SAGES guidelines for Minimally Invasive Treatment of Adrenal Pathology

Year: 2013
AGREE II score: Unavailable
Developer organization: Society of American Gastrointestinal and Endoscopic Surgeons
A clinical practice guideline for patients with adrenal diseases, including pheochromocytoma, carcinoma, and adrenal gland neoplasms. The guideline examines minimally invasive treatment techniques, specifically focusing on appropriate resection and technical details. Outcomes of interest reduced hospital stay and postoperative pain.

Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement

Year: 2013
AGREE II score: Unavailable
Developer organization: American Society of Clinical Oncology
A clinical practice guideline for survivors of colorectal cancer. The guideline examines appropriate follow-up and surveillance for stage II and III cancer survivors, including appropriate timing, supportive care, and secondary prevention. Outcomes of interest include improved prevention through lifestyle changes and increasing carcinoembryonic antigen testing when necessary.

Esophageal Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over 18 years of age with esophageal cancer, including both squamous cell and adenocarcinoma. The guideline provides recommendations on diagnostic work-up, staging, treatment options for potentially curable cancer, and management options for incurable cancer. Outcomes of interest include survival (overall, progression-free, 5-year), morbidity, toxicity, and rate of sudden death.

Anal Canal Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults over 18 years of age with squamous cell carcinomas that arise in the anal canal. The guideline discusses diagnostic work-up, staging, and the goals of therapy and recommendations for both potentially curable, locally recurrent, and metastatic cancer of the anal canal. Follow-up care is also reviewed.

The Committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma

Year: 2013
AGREE II score: Available
Developer organization: Japan Society of Hepatology
This is a clinical practice guideline for patients diagnosed with or at risk of developing hepatocellular carcinoma. The guideline reviews prevention, diagnosis and surveillance, surgery, percutaneous ablation therapy, transcatheter arterial chemoembolization (TACE), chemotherapy, and radiation therapy. Post-treatment surveillance, prevention of recurrence, and treatment of recurrent cancer are also reviewed. Outcomes of interest include survival, recurrence, disease progression, sensitivity, specificity, and predictive values of diagnostic tests, efficacy of surveillance and treatment techniques, surgical complications, and postoperative mortality.

Provincial Colorectal Cancer Treatment Guidelines

Year: 2013
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with colorectal cancer. The guideline examines work up steps, and includes recommendations for resectable and unresectable colon and rectal cancers. Outcomes of interest include high response rates with combination chemotherapy and improved therapies for K-RAS mutated tumours.

Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer

Year: 2013
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with clinically resectable or resected stage II or III rectal cancer. The guideline reviews the use of pre- and post-operative therapy including chemotherapy and radiotherapy as treatment options. Outcomes of interest include survival (overall, cause-specific), quality of life, acute and late toxicities, and postoperative morbidity (within 30 days of surgery).

Management of Squamous Cell Cancer of the Anal Canal

Year: 2013
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with a primary diagnosis of biopsy-proven squamous cell cancer of the anal canal, including basaloid, cloacogenic, and transitional cell tumours. The guideline reviews treatment and follow-up care for squamous cell cancer, with radiotherapy and chemotherapy discussed as treatment options. Outcomes of interest include colostomy rate, local failure, survival, adverse effects (acute and late), and quality of life.

Colorectal Screening For Cancer Prevention in Asymptomatic Patients

Year: 2013
AGREE II score: Unavailable
Developer organization: British Columbia Medical Services Commission
This is a clinical practice guideline for asymptomatic patients over 19 years of age. The guideline provides recommendations on screening for colorectal cancer stratified by age and risk. Risk factors are discussed, and screening procedures are reviewed including fecal occult blood test (FOBT), colonoscopy, flexible sigmoidoscopy, and CT colonography.

Practice Parameters for the Management of Rectal Cancer (Revised)

Year: 2013
AGREE II score: Unavailable
Developer organization: American Society of Colon and Rectal Surgeons
A clinical practice guideline for the management of colorectal carcinoma. The guideline examines preoperative assessment, staging, surgical techniques, and operative considerations. Outcomes of interest include improved surgical management and reduced recurrence rate.

Follow-up of Colorectal Polyps or Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: British Columbia Medical Association
This is a guideline for patients who have received curative resection of colorectal cancer (CRC) or polypectomy. The guideline provides recommendations on follow-up procedures and intervals depending on risk group. Follow-up visits are outlined and procedures including colonoscopy, imaging and x-rays, tumour markers, and fecal occult blood tests are reviewed. Long-term surveillance is also discussed.

Mitotane for the Management of Adrenocortical Carcinoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for the management of patients diagnosed with adrenocortical carcinoma. The guideline examines the use of adjuvant mitotane therapy in resectable and unresectable carcinomas, and options for combination therapy. Outcomes of interest include lower rate of recurrence post-surgery and prolonged survival in children.

Long-Term Management of the Successful Adult Liver Transplant: 2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation

Year: 2013
AGREE II score: Unavailable
Developer organization: American Association for the Study of Liver Diseases
This clinical practice guideline reviews diagnostic, therapeutic, and preventive aspects of care for adult patients who have successfully undergone liver transplantation (LT). Topics include post-transplant monitoring and management of complications, as well as longer-term prevention and management of associated health conditions such as systemic and infectious diseases. Health promotion after LT is also discussed, with specific recommendations provided for bone health, nutrition and obesity, and reproductive health. Topics specific to oncology include screening for de novo cancer and management of recurrent or persistent cancer in LT patients.

Management of Gastric Cancer in Asia: Resource-Stratified Guidelines

Year: 2013
AGREE II score: Unavailable
Developer organization: Asian Oncology Summit
A clinical practice guideline for patients with gastric cancers. The guideline examines diagnosis and management, including regional and resource-based recommendations. Outcomes of interest include increased HER2 testing and increased post-operative chemotherapy for palliative patients.

Early Stage Rectal Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over 18 years of age with early stage rectal cancer. The guideline reviews diagnostic work-up, staging, and treatment options including surgical resection and chemotherapy.

Early Stage Colon Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults over 18 years of age with early stage colon cancer. The guideline provides recommendations on diagnostic work-up, staging, and treatment including a review of recommended chemotherapy regimes.

Cholangiocarcinoma and Gallbladder Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients with biliary tract cancer. The guideline examines management, with specific focus on surgical resection for potentially resectable disease and palliative radiotherapy for unresectable disease. Outcomes of interest include improved recommendations for establishing resectability and reductions in endoscopic retrograde cholangiopancreatogram.

Guidelines for Breast, Cervical and Colorectal Cancer Screening

Year: 2013
AGREE II score: Unavailable
Developer organization: CancerCare Manitoba
This guideline provides screening recommendations for breast, cervical, and colorectal cancer, based on age and risk factors. Management of test results including mammography, cytology, occult blood test (FOBT) and colonoscopy are discussed, and potential benefits and harms are reviewed. Other testing procedures include ultrasound, stereotactic core biopsy, colposcopy, endocervical curettage, endometrial biopsy, flexible sigmoidoscopy, and colonoscopy.

Revised Guidelines for the Clinical Management of Lynch Syndrome (HNPCC): Recommendations by a Group of European Experts

Year: 2013
AGREE II score: Unavailable
Developer organization: Mallorca Group
This is a clinical practice guideline regarding the clinical management of Lynch syndrome (LS) (previously referred to as hereditary non-polyposis colorectal cancer; HNPCC). The guideline looks at improving the identification of LS, optimal surveillance protocols for various cancers, the role of prophylactic hysterectomy with or without oophorectomy, and appropriate surgical treatment for CRC. Other topics of discussion include the influence of lifestyle and environmental factors on the development of CRC in LS, the role of aspirin in the management of LS, prenatal diagnosis (PND) and preimplantation genetic diagnosis (PGD) in LS, and the psychosocial implications of genetic testing and surveillance.

Thyroid Nodules and Differentiated Thyroid Cancer: Update on the Brazilian Consensus

Year: 2013
AGREE II score: Unavailable
Developer organization: Sociedade Brasileira de Endocrinologia e Metabologia
A clinical practice guideline for patients with thyroid nodules and at risk for thyroid cancer. The guideline examines diagnosis for normal and abnormal thyroid-stimulating hormone tests, and treatment including surgical options. Outcomes of interest include reductions in unnecessary procedures and improved recommendations for pregnant patients.

Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study

Year: 2013
AGREE II score: Unavailable
Developer organization: RAND Corporation
A clinical practice guideline for patients undergoing surgery for gastric cancer. The guideline examines surgical quality with specific focus on staging and surgical margins. Outcomes of interest include improved recommendations for multiorgan resection and improved staging-based resection choice.

What Provider Volumes and Characteristics are Appropriate for Gastric Cancer Resection? Results of an International RAND/UCLA Expert Panel

Year: 2013
AGREE II score: Unavailable
Developer organization: International RAND/UCLA expert panel
This is a guideline for patients with gastric adenocarcinoma who are undergoing gastrectomy. The guideline reviews the relationship between surgical volumes including surgeon and hospital volumes, and surgical outcome. Hospital characteristics such as whether the hospital contains a level I intensive care unit are also examined. Outcomes of interest include procedure-related morbidity, procedure-related mortality, and survival related to hospital volume, hospital specialization, surgeon volume, or surgeon training.

Chemotherapy or Radiotherapy for Resectable Pancreatic Adenocarcinoma

Year: 2013
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with resectable pancreatic adenocarcinoma for whom a pancreatectomy is planned. The guideline reviews pre- and post-operative treatment options including radiotherapy and chemotherapy. Outcomes of interest include overall survival, quality of life, and adverse effects.

Octreotide for the Management of Neuroendocrine Tumours

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for the management of neuroendocrine tumours of the gastrointestinal tract, pancreas, lungs, thyroid, parathyroid, adrenal glands, and pituitary gland, and of unknown origin. The guideline examines symptom management and dosing regimens for treatment with octreotide. Outcomes of interest include slowed tumour progression and improved prophylactic use.

Role of Endoscopy in the Staging and Management of Colorectal Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: American Society for Gastrointestinal Endoscopy
A clinical practice guideline for the use of gastrointestinal endoscopy in the staging and management of colorectal cancer in adult patients. The guideline examines staging, endoscopic management, and endoscopic resection in colonic obstructions and colorectal neoplasia. Outcomes of interest include improved differentiation between benign and malignant lymph nodes through endoscopic ultrasound-guided fine-needle aspiration.

The Society of Thoracic Surgeons Guidelines on the Diagnosis and Staging of Patients with Esophageal Cancer

Year: 2013
AGREE II score: Available
Developer organization: Society of Thoracic Surgeons
This clinical practice guideline reviews the diagnosis and staging of esophageal cancer in adult patients. Procedures including flexible endoscopy with biopsy, CT, PET, endoscopic ultrasonography (EUS), Endoscopic mucosal resection (EMR), and laparoscopy are discussed. Outcomes of interest include sensitivity, specificity, and accuracy of diagnostic procedures.

Bowel Preparation for Colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Year: 2013
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
A clinical practice for patients with cervical intraepithelial neoplasia. The guideline examines the use of cryotherapy based on lesion size and other risk factors. Recommendations on technique are included, and comparisons are made to loop electrosurgical excision procedures.

Prevention and Treatment of Rash in Patients Treated with EGFR Inhibitor Therapies

Year: 2012
AGREE II score: Available
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with advanced non-small cell lung cancer, colorectal cancer, head/neck cancer, or breast cancer, that is treated with the epidermal growth factor receptor (EGFR) inhibitors cetuximab, erlotinib, gefitinib, panitumumab, or lapatinib, either alone or in combination with other treatments. The guideline examines the prevention and management of a papulopustular rash that commonly develops as a side effect of EGFR inhibitor therapy. Topics of discussion include prevention and prophylactic treatment of rash, clinical management, and supportive care. Outcomes of interest include rash severity, rate of recurrence, and response to treatment.

Thymic Neoplasms

Year: 2012
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients with thymic neoplasms. The guideline examines staging based treatment and follow up, focusing on surgical resection and postoperative radiotherapy. Outcomes of interest include reduced relapse and improved multimodal treatment regimens.

Guidelines for Perioperative Care in Elective Rectal/Pelvic Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations

Year: 2012
AGREE II score: Unavailable
Developer organization: Enhanced Recovery After Surgery Group
This clinical practice guideline discusses pre- and peri-operative care interventions for patients undergoing elective rectal or pelvic surgery. Comparisons are made between rectal resection and colon resection recommendations, specifically in pre-operative counselling and optimisation. Outcomes of interest include rates of anastamotic leaks, length of hospital stay, and post-operative morbidity.

The Role of Liver Resection in Colorectal Cancer Metastases

Year: 2012
AGREE II score: Available
Developer organization: Cancer Care Ontario
This clinical practice guideline reviews surgical management of patients with liver metastases from colorectal cancer who have had or will have a complete resection of the primary cancer, and who meet the surgical criteria for the resection of liver-only metastases. The guideline examines the role of liver resection in special cases of liver plus extrahepatic metastases (EHM). The use of perioperative chemotherapy is also discussed. Outcomes of interest include median survival, three- and five-year survival, recurrence rate, postoperative complications, and chemotherapy-related hepatic injury.

Referral of Patients with Suspected Colorectal Cancer by Family Physicians and Other Primary Care Providers

Year: 2012
AGREE II score: Available
Developer organization: Cancer Care Ontario
This clinical guideline examines the management of adult patients presenting in primary care settings with signs and/or symptoms of colorectal cancer. Clinical presentation (focused history and physical examination), referral, and recommendations to reduce diagnostic delay are discussed. Assessment techniques include digital rectal examination, physical examination, complete blood count (CBC), fecal occult blood test (FOBT), computed tomographic (CT) colonography and double-contrast barium enema (DCBE). Outcomes of interest are positive predictive values for colorectal cancer.

Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel

Year: 2012
AGREE II score: Unavailable
Developer organization: Other, please specify below:
This is a clinical practice guideline for the management of patients with serrated lesions of the colorectum. The guideline reviews pathology, molecular features, epidemiology, and detection of lesions and provides recommendations regarding removal of lesions and post-polypectomy surveillance. Serrated polyposis syndrome (SPS) is also discussed.

Learning, Techniques, and Complications of Endoscopic Ultrasound (EUS)-Guided Sampling in Gastroenterology: European Society of Gastro- intestinal Endoscopy (ESGE) Technical Guideline

Year: 2012
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This clinical practice guideline examines endoscopic ultrasound (EUS)-guided sampling in gastroenterology. Topics of discussion include learning of procedure, surgical techniques, complications and their prevention, and the processing of specimens obtained with EUS-guided fine needle aspiration or EUS-guided Trucut biopsy. Outcomes of interest include diagnostic accuracy, malignancy, morbidity, complication rate and procedure-related mortality.

Guidelines for Perioperative Care in Elective Colonic Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations

Year: 2012
AGREE II score: Unavailable
Developer organization: Enhanced Recovery After Surgery Group
A clinical practice guideline for the perioperative care of patients undergoing elective colonic surgery. The guideline examines pre- and peri-operative nutrition and analgesic care options, as well as postoperative complication reduction options. Outcomes of interest include reduced length of hospital stay, re-admissions, and mortality.

European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis: First Edition

Year: 2012
AGREE II score: Available
Developer organization: International Agency for Research on Cancer
A clinical practice guideline for the screening and surveillance of patients at risk for colorectal cancer. The guideline examines quality assurance and professional requirements for common screening procedures, such as endoscopy and fecal occult blood tests, and including recommendations for follow-up and treatment timing. Outcomes of interest include improved safety and improved patient experience.

Practice Parameters for Anal Squamous Neoplasms

Year: 2012
AGREE II score: Unavailable
Developer organization: American Society of Colon and Rectal Surgeons
A clinical practice guideline for patients with squamous-cell carcinoma of the anus. The guideline examines pre-treatment evaluation, treatment, and post-treatment surveillance, with specific recommendations for HIV-positive patients. Outcomes of interest include increased support for intensity-modulated radiation therapy-based chemoradiotherapy as a primary treatment, and specifically for HIV-positive patients with higher toxicity risks.

Highlights of the EORTC St. Gallen International Expert Consensus on the Primary Therapy of Gastric, Gastroesophageal and Oesophageal Cancer – Differential Treatment Strategies for Subtypes of Early Gastroesophageal Cancer

Year: 2012
AGREE II score: Unavailable
Developer organization: European Organisation for Research and Treatment of Cancer
A clinical practice guideline for gastroesophageal cancer treatment and staging recommendations. The guideline examines surgical and systemic therapy treatment options for primary care in a variety of gastroesophageal cancers. Outcomes of interest include use of staging endosonography and laparoscopy and primary treatment strategies. The use of endosonography, laparoscopy, and PET-CT scans in routine staging is also examined.

Quality in Screening Colonoscopy: Position Statement of the European Society of Gastrointestinal Endoscopy (ESGE)

Year: 2012
AGREE II score: Unavailable
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This clinical practice guideline reviews the use of colonoscopy for colorectal cancer screening. The guidelines reviews colonoscopy preparation and provides recommendations for colonoscopy procedure and cleaning and disinfection of equipment. Recommendations are also made for experience of colonoscopists, recording of adverse outcomes, and the colonoscopy report. Outcomes of interest include detection rate and adverse events.

Guideline Colon Capsule Endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Year: 2012
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This clinical practice guideline reviews colon capsule endoscopy (CCE) for use in colorectal cancer screening. Indications and contraindications, bowel preparation, and reporting and workup of CCE results are discussed. Positive and negative predictive value, sensitivity, and specificity of CCE are considered.

Guidelines for Perioperative Care for Pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS) Society Recommendations

Year: 2012
AGREE II score: Unavailable
Developer organization: Enhanced Recovery After Surgery Group
This is a clinical practice guideline on optimal perioperative care for patients undergoing pancreaticoduodenectomy. The guideline provides recommendations for pre- and perioperative care as well as surgical technique. Outcomes of interest include morbidity, recovery rate, and cost.

Consensus Statements for Management of Barrett’s Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process

Year: 2012
AGREE II score: Available
Developer organization: Barrett's Dysplasia and Cancer Taskforce (BAD CAT)
This clinical practice guideline provides recommendations on the management of patients with Barrett's esophagus (BE) and low-grade dysplasia (LGD), high-grade dysplasia (HGD), or early- stage esophageal adenocarcinoma (EA). Diagnosis of BE and HGD, risk factors for EA and surveillance of at-risk patients, and treatment of HGD and early EA are discussed.

Practice Parameters for the Management of Colon Cancer

Year: 2012
AGREE II score: Unavailable
Developer organization: American Society of Colon and Rectal Surgeons
A clinical practice guideline for patients with colon cancer. The guideline examines risk assessment and treatment, primarily through surgical resection. Outcomes of interest include improved prediction of outcomes through histologic grading and reduced surgical morbidity in palliative procedures.

Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)

Year: 2012
AGREE II score: Unavailable
Developer organization: Endocrine Society
This is a clinical practice guideline for the management of patients with multiple endocrine neoplasia (MEN) type 1 (MEN1) and their families. Recommendations are provided for genetic testing and screening, diagnosis, and treatment of MEN1 related tumours. Organization of care is also discussed.

Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2012
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for head and neck cancer patients (HNCPs) undergoing radiotherapy. The guideline reviews dysphagia mechanisms and causes in HNCPs and provides recommendations on the management of patients undergoing radiotherapy who have pre-treatment dysphagia or are at risk for dysphagia. The occurrence of dysphagia in post-surgical radiotherapy or after chemoradiotherapy is also discussed.

Guidelines for the Diagnosis and Treatment of Cholangiocarcinoma: An Update

Year: 2012
AGREE II score: Unavailable
Developer organization: British Society of Gastroenterology
This is a clinical practice guideline for the management of patients with cholagiocarcinoma or suspected cholagiocarcinoma. The guideline discusses risk factors, diagnosis and staging, and treatment options. Outcomes of interest include survival, time-to-progression, tumour control rate, and rate of surgical complications.

Recommendations from the EGAPP Working Group: Can Testing of Tumor Tissue for Mutations in EGFR Pathway Downstream Effector Genes in Patients with Metastatic Colorectal Cancer Improve Health Outcomes by Guiding Decisions Regarding Anti-EGFR Therapy?

Year: 2012
AGREE II score: Unavailable
Developer organization: Evaluation of Genomic Applications in Practice and Prevention Working Group
This recommendation statement explores the use of pharmacogenomic testing of tumour in patients with metastatic colorectal cancer to predict response to anti-EGFR antibody therapy (cetuximab or panitumumab). The guideline reviews analytic and clinical validity of testing for selected pharmacogenomic tests including codon 12 and 13 mutations in KRAS, the BRAF V600E mutation, variants in NRAS and in PIK3CA, and loss of PTEN and AKT protein expression. Outcomes of interest include overall or progression-free survival and treatment-related adverse events.

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

Year: 2012
AGREE II score: Available
Developer organization: American Gastroenterological Association
A clinical practice guideline for colorectal cancer screening in asymptomatic patients. The guideline examines screening and surveillance intervals given the potential presence of adenomatous polyps and previous polypectomies. Outcomes of interest include colonoscopy quality and follow up surveillance procedures.

Management of Precancerous Conditions and Lesions in the Stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

Year: 2011
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
A clinical practice guideline for the management of patients with premalignant atrophic gastritis, intestinal metaplasia, and epithelial dysplasia at risk for gastric cancers. The guideline makes recommendations for staging, treatment, and follow-up for precancerous gastric conditions to improve the diagnosis of early stage cancer. Outcomes of interest include Helicobacter pylori eradication, pharmacological options, and an analysis of patient benefits in terms of cost-effectiveness.

Biliary Stenting: Indications, Choice of Stents and Results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline

Year: 2011
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This clinical practice guideline examines biliary stenting and provides recommendations on when, how, and with which stent to perform biliary drainage. Treatment of benign conditions and management of complications are also reviewed. Outcomes of interest include treatment success and complications.

Clinical Practice Guidelines for Surveillance Colonoscopy

Year: 2011
AGREE II score: Available
Developer organization: Cancer Council Australia
This is a clinical practice guideline for patients known to be at above-average risk for colorectal cancer (CRC) development, such as patients who have already had adenomatous polyps removed or surgery for CRC and patients with inflammatory bowel disease. The guideline discusses colonoscopic surveillance after polypectomy, the role of surveillance colonoscopy after curative resection for colorectal cancer, and colonoscopic surveillance and management of dysplasia in inflammatory bowel disease. Psychosocial aspects, socio-economic factors, and economic considerations are also discussed. Outcomes of interest include adenoma detection rates, testing sensitivity, and cost effectiveness.

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2010 for the Treatment of Colorectal Cancer

Year: 2011
AGREE II score: Unavailable
Developer organization: Japanese Society for Cancer of the Colon and Rectum (JSCCR)
This clinical practice guideline provides an overview on the treatment of colorectal cancer. Treatment strategies are outlined for all stages of colorectal cancer as well as for recurrences and hematogenous metastases, and treatment options including chemotherapy and radiotherapy are reviewed. Palliative care and surveillance after surgery are also discussed. Outcomes of interest include survival and recurrence rate.

Guidelines for the Management of Gastroenteropancreatic Neuroendocrine (Including Carcinoid) Tumours (NETs)

Year: 2011
AGREE II score: Unavailable
Developer organization: UK and Ireland Neuroendocrine Tumour Society
This is a clinical practice guideline for patients with gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Genetic risk factors, diagnostic assessment including imaging and pathology, and treatment are discussed. Special topics of interest include genetic risk factors and association of NETs with carcinoid heart disease (CHD). Outcomes of interest include survival rates, sensitivity of diagnostic testing procedures, adverse effects and quality of life.

Clinical Practice Guideline for Surveillance Colonoscopy – In Adenoma Follow-up; Following Curative Resection of Colorectal Cancer; and for Cancer Surveillance in Inflammatory Bowel Disease

Year: 2011
AGREE II score: Available
Developer organization: Cancer Council Australia
This is a clinical practice guideline for adults aged 19 and over. The guideline examines surveillance colonoscopy after polypectomy or curative resection for colorectal cancer, and in inflammatory bowel disease. Advances in colonoscopy, CT colonography, and other methods of investigation are also discussed, as well as psychosocial effects of colonoscopy and socioeconomic factors. Outcomes of interest include survival, patient experience, and accuracy of colonoscopy.

CAR CT Colonography Standards

Year: 2010
AGREE II score: Unavailable
Developer organization: Canadian Association of Radiologists
This is a clinical and professional practice guideline that recommends standards of best practice for the use of CT colonography in the screening and diagnostic assessment of colorectal cancer. The guideline discusses patient information and consent, CT technique, patient experience and safety, and interpretation of results. Additional topics include radiologist training/assessment, use of endoscopy as a post-CT test, and resource allocation.

Colorectal Cancer Screening Clinical Practice Guideline

Year: 2010
AGREE II score: Available
Developer organization: Kaiser Permanente
This is a clinical practice guideline for adults with average or high risk for colorectal cancer. The guideline discusses risk factors for colorectal cancer, effectiveness of screening tests, and screening strategies based on age and risk. The following screening techniques are compared: high-sensitivity guaiac fecal occult blood test (gFOBT), immunochemical fecal occult blood test (iFOBT/FIT), flexible sigmoidoscopy, colonoscopy, standard guaiac FOBT (gFOBT), air contrast barium enema, CT colonography, and fecal DNA testing. Outcomes of interest include colon cancer incidence, morbidity, and mortality, as well as outcomes of screening intervention including test effectiveness and adverse effects.

Colonoscopy Recommendations

Year: 2008
AGREE II score: Unavailable
Developer organization: Cancer Care Nova Scotia
This is a clinical practice guideline for patients requiring colon cancer screening, examining colonoscopy standards. Important aspects include ideal polyp detection conditions, monitoring during the procedure, and follow-up care.